National Institute for Health and Care Excellence

Consultation

Perioperative care in adults

[C] Evidence review for preoperative risk stratification tools

NICE guideline

Prognostic evidence review

November 2019

Draft for Consultation

This evidence review was developed by the National Guideline Centre



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2019. All rights reserved. Subject to Notice of rights.

Contents

| | Preo | perativ | e risk stratification tools | 6 |
|-----|-------|----------|--|------|
| | 1.1 | identify | v question: Which validated preoperative risk stratification tools best y increased risk of mortality and morbidity in adults who will be going surgery? | 6 |
| 1.2 | | - | uction | |
| | 1.3 | | table | |
| 1.4 | | | ıl evidence | |
| | | 1.4.1 | Included studies | 7 |
| | | 1.4.2 | Excluded studies | 7 |
| | | 1.4.3 | Summary of clinical studies included in the evidence review | 8 |
| | | 1.4.4 | Quality assessment of clinical studies included in the evidence review | 16 |
| | 1.1 | Discrir | nination | 16 |
| | 1.2 | Calibra | ation | 17 |
| | 1.3 | Econo | mic evidence | 19 |
| | | 1.3.1 | Included studies | 19 |
| | | 1.3.2 | Excluded studies | 19 |
| | 1.4 | Evider | nce statements | 19 |
| | | 1.4.1 | Clinical evidence statements | 19 |
| | | 1.4.2 | Health economic evidence statements | 20 |
| | 1.5 | The co | ommittee's discussion of the evidence | 20 |
| | | 1.5.1 | Interpreting the evidence | 20 |
| | | 1.5.2 | Cost effectiveness and resource use | 22 |
| | | 1.5.3 | Other factors the committee took into account | . 22 |
| αA | pendi | ces | | 36 |
| • | Appe | endix A: | Review protocols | 36 |
| | Appe | ndix B: | · | |
| | | B.1 CI | inical search literature search strategy | 42 |
| | | B.2 H | ealth Economics literature search strategy | . 45 |
| | Appe | ndix C: | Clinical evidence selection | . 50 |
| | Appe | ndix D: | Clinical evidence tables | 51 |
| | Appe | ndix E: | PROBAST checklist | 77 |
| | Appe | ndix F: | C-statistic plots | 84 |
| | Appe | ndix G: | Calibration plots | . 90 |
| | Appe | ndix H: | Health economic evidence selection | . 93 |
| | Appe | ndix I: | Health economic evidence tables | . 94 |
| | Appe | endix J: | Excluded studies | 95 |
| | | J.1 Ex | cluded clinical studies | 95 |
| | | J.2 Ex | cluded health economic studies | . 98 |

1 Preoperative risk stratification tools

1.1 Review question: Which validated preoperative risk stratification tools best identify increased risk of mortality and morbidity in adults who will be undergoing surgery?

1.2 Introduction

The conundrum facing all perioperative clinicians when evaluating patients for surgery remains how best to evaluate and quantify the risk of undergoing the anticipated procedure. There are a number of reasons why this is a key element of evaluation during the preoperative clinical encounter. Firstly, establishing objective understanding of the anticipated mortality and morbidity risk allows and directs discussions with other involved clinicians about the appropriateness of the planned surgery and whether it should proceed as planned, should be abbreviated, or whether alternative non-surgical options should be considered. Secondly, being able to quantify morbidity risk allows planning for post-operative destination, discussions about quality of life and recovery or convalescence and to give insight to the patient about the anticipated clinical course. Understanding these elements allows frank discussions about what the patients actually wish to achieve from the surgical encounter. Furthermore this opens the discussions amongst all parties for shared decision making about the best outcome decision that will meet the goals of the involved parties.

Thus it becomes incumbent on perioperative clinicians to find robust, reliable and accurate tools that will allows us to determine bespoke perioperative risk for each individual patient allowing these discussions and decisions to proceed smoothly. Current practice appears to be that many perioperative clinicians use risk stratification tools but not in a uniform or unified fashion. Different tools are used with different sensitivities and specificities and are not uniformly applied to all surgical populations. There does not exist a national recommendation or standard on which tools to use, how they should be applied, nor even that a risk stratification tool should be consistently used in the perioperative setting at all.

The committee agreed this was a fundamental aspect that required investigation of existing evidence around such tools with the intention to set a recommendation standard in this area of perioperative care.

1.3 PICO table

For full details see the review protocol in Appendix A:.

Table 1: PICO characteristics of review question

| Population | Adults 18 years and over undergoing surgery. |
|------------------|---|
| Risk tool | Validated risk stratification tools: P-POSSUM score (Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity) SORT (Surgical Outcome Risk Tool) NSQIP (National Surgical Quality Improvement Program) universal surgical risk calculator |
| Target condition | MortalityMorbidity |
| Outcome measures | Sensitivity, specificity, predictive values Area under the ROC curve (c-statistic) |

Predicted risk versus observed risk (calibration)

• Prospective and retrospective cohort studies

1 1.4 Clinical evidence

1.4.1 Included studies

Fifty studies were included in the review; 11, 14, 17, 18, 20, 22, 24, 26, 31, 32, 36, 38, 43, 45, 46, 49, 52, 54, 57, 58, 60, 64, 65, 72, 78, 82, 87, 88, 95, 99, 110, 127, 129, 133, 140, 142, 146, 148, 152, 155, 156, 160, 161, 167, 169, 172, 173, 176, 177, 179 these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3).

See also the study selection flow chart in Appendix C: and study evidence tables in Appendix B:

9 1.4.2 Excluded studies

10 See the excluded studies list in appendix J.

3.3 Summary of clinical studies included in the evidence review

Table 2: Summary of studies included in the evidence review

| Study | Population | Risk tool | Outcomes |
|-------------------------------------|--|----------------------------|-------------------------|
| Baker 2018 ¹¹ | Patients scheduled for surgery under general anaesthetic (GA) with entry into the Peritoneum. N=298 | ACS NSQIP risk calculator | Morbidity • c-statistic |
| Bennett-Guerrero 2003 ¹⁴ | Two cohorts of patients undergoing major, non-cardiac surgery over the same time interval. N=1056 (USA) N=1539(UK) | P-POSSUM | Mortality • calibration |
| Blair 2018 ¹⁷ | Retrospective review of a single institution, multi-surgeon, database of all patients undergoing partial nephrectomy (PN) for renal cell carcinoma. N=470 | ACS NSQIP risk calculator | Mortality |
| Bodea 2018 ¹⁸ | Elective surgery patients undergoing elective Pancreaticoduodenectomy for periampullary malignant tumours. N=113 | P-POSSUM | Mortality |
| Bonaventura 2019 ²⁰ | Patients undergoing cholecystectomy for acute cholecystitis N=271 | Charlson Comorbidity index | Morbidity • c-statistic |
| Boyd 2019 ²² | Women patients 18 years or older undergoing surgery for pelvic organ prolapse or incontinence by all routes. | ACS NSQIP risk calculator | Morbidity • c-statistic |

| Study | Population | Risk tool | Outcomes |
|-----------------------------|--|----------------------------|-----------------------------|
| | N=731 | | |
| Bronheim 2018 ²⁴ | Adult patients undergoing posterior lumbar decompression surgery N=52,066 | ASA | Mortality |
| Bulow 2019 ²⁶ | Patients treated with hip arthroplasty for a femoral neck fracture. N=43,224 | Charlson Comorbidity index | Mortality • c-statistic |
| Cengiz 2014 ³¹ | Consecutive patients undergoing colorectal cancer surgery between 2002 and 2012 in third-level healthcare centres. N=335 | POSSUM P- POSSUM | Mortality • c-statistic |
| Chun 2018 ³² | Patients who had undergone spinal surgery for various spine diseases at a single tertiary care centre. N=217 | POSSUM E-PASS | Complications • c-statistic |
| Cologne 2015 ³⁶ | Consecutive laparoscopic colon resections performed on an elective basis from by two colorectal surgeons at a tertiary referral centre. N=116 | ACS NSQIP risk calculator | Mortality |
| Dahlke 2014 ³⁸ | Data obtained from the ACS NSQIP participant file 2011 release for patients undergoing a broad range of surgeries across all surgical specialities. N=238649 | ACS NSQIP risk calculator | Morbidity • c-statistic |
| Dutta 2011 ⁴³ | Patients undergoing oesophago- gastric cancer resections. | POSSUM P- POSSUM | Mortality • c-statistic |

| Study | Population | Risk tool | Outcomes |
|----------------------------|---|---|--|
| | N=121 | | calibrationAny complicationc-statisticcalibration |
| Egberts 2011 ⁴⁵ | The medical records of 143 patients with cutaneous melanoma who underwent a radical lymph node dissection (RLND). N=143 | POSSUM | Mortality |
| Egberts 2011 ⁴⁶ | The medical records of patients undergoing surgery for inflammatory bowel disease (IBD). N=191 | POSSUM | Mortality |
| Filip 2014 ⁴⁹ | Patients diagnosed with oesophageal cancer in whom surgery was performed. N=137 | POSSUM P-POSSUM ASA classification Charlson Comorbidity index | Mortality |
| Fu 2019 ⁵² | Patients who underwent total shoulder arthroplasty were identified in the NSQIP. N=10,527 | ASA classification Charlson Comorbidity index | Morbidity • c-statistic |
| Golan 2018 ⁵⁴ | Patients in prospectively maintained database who underwent open RC with either ileal conduit or orthotopic neobladder urinary diversion for bladder cancer. N=954 | ACS NSQIP risk calculator | Mortality |
| Hirose 2014 ⁵⁷ | Consecutive patients who underwent spinal surgery. | POSSUM E-PASS | Mortality • c-statistic |

| Study | Population | Risk tool | Outcomes |
|----------------------------|--|--|----------------------------|
| | N=601 | | Morbidity • c-statistic |
| Hirose 2015 ⁵⁸ | Retrospective review of consecutive patients who underwent spinal surgery. N=275 | E-PASS | Mortality • c-statistic |
| Hobson 2007 ⁶⁰ | All patients undergoing surgery in the emergency theatre of the Leicester general hospital over a 4-month period. N=163 | POSSUM P-POSSUM | Mortality |
| Huisman 2014 ⁶⁴ | Recruitment took place in 6 different countries at 11 medical centers between September 2008 and January 2012 and included cancer patients scheduled for elective surgery. N=263 | ASA classification | Morbidity • c-statistic |
| Igari 2013 ⁶⁵ | Patients undergoing general surgical procedures at Ohta Nishinouchi General Hospital. N=593 | POSSUM P-POSSUM | Mortality |
| Katlic 2019 ⁷² | Geriatric surgical patients undergoing major elective surgery including cardiac, thoracic, vascular, orthopaedic, surgical oncology, general surgery, urologic and neurologic. N=1025 | ASA Score Charleston Comorbidity index | Complication • c-statistic |
| Kim 2018 ⁷⁸ | Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty. N=90,491 | Charleston Comorbidity index | Mortality |

| Study | Population | Risk tool | Outcomes |
|-----------------------------|---|---|-------------------------|
| Kong 2013 ⁸² | Major colorectal operations performed at Geelong hospital and Western Hospital from 2008-2010 N=863 | POSSUM P-POSSUM | Mortality • calibration |
| Kwok 2011 ⁸⁷ | Data from ACS NSQIP including very elderly patients aged 80+ undergoing emergency colon surgery. N=1730 | ASA classification Surgical risk scale | Mortality |
| Lakomkin 2018 ⁸⁸ | Patients undergoing spinal tumour resection. N=2,170 | ASA score Charlston Comorbidity Index | Mortality • c-statistic |
| Lima 2019 ⁹⁵ | Patients over 60 years old scheduled to undergo elective procedures under general, regional or combined anaesthesia for general, gynaecological, plastic, vascular, or orthopaedic surgeries. N=235 | P-POSSUM | Mortality • c-statistic |
| Markovic 2018 ⁹⁹ | Pilot study included patients who were being prepared for one of the major non-cardiac surgeries under general anaesthesia. N=78 | ASA classification ACS NSQIP risk calculator SORT | Mortality • c-statistic |
| Ngulube 2019 ¹¹⁰ | Patients aged 18 years and above undergoing a major general surgical procedure as defined by the British United Provident Association, with timing ranging from elective to emergency. N=181 | POSSUM P-POSSUM | Mortality |
| Reis 2019 ¹²⁸ | Patients admitted to surgical ICU after open vascular surgery. N=833 | POSSUM | Mortality |

| Study | Population | Risk tool | Outcomes |
|------------------------------|---|--------------------------------|-------------------------|
| Rivard 2016 ¹²⁹ | Patients who underwent laparotomy on the gynecologic oncology service at a single academic hospital. N=1094 | ACS NSQIP risk calculator | Mortality |
| Saafan 2019 ¹³³ | Patients presenting to ER and diagnosed and operated for perforated duodenal ulcers. N=152 | ASA classification | Morbidity • c-statistic |
| Shaker 2019 ¹⁴⁰ | Gynaecologic oncology patients aged >70 years undergoing laparotomy. N=200 | ACS NSQIP risk calculator | Mortality |
| Sharrock 2017 ¹⁴² | Consecutive hospital admissions of patients aged 70 or over admitted as an emergency for abdominal surgery. N=193 | P-POSSUM ASA classification | Mortality |
| Simpson 2018 ¹⁴⁶ | Patients over 80 years old undergoing emergency laparotomy N=103 | P-POSSUM | Mortality • c-statistic |
| Slim 2006 ¹⁴⁸ | Patients undergoing open or laparoscopic surgery (electively or on emergent basis) for colorectal cancers or diverticular disease. N=1421 | POSSUM P-POSSUM | Mortality |
| Suresh 2019 ¹⁵² | Patients who underwent panniculectomy. N=264 | ACS NSQIP risk calculator | Morbidity • c-statistic |

| Study | Population | Risk tool | Outcomes |
|---------------------------------|---|-------------------------------------|-------------------------|
| Teeuwen 2011 ¹⁵⁵ | Patients older than 15 years undergoing colorectal resection between January 2003 and January 2008 in the Radboud University Nijmegen Medical Centre. N=734 | POSSUM P-POSSUM | Mortality |
| Teoh 2017 ¹⁵⁶ | All patients undergoing minimally invasive surgery on the gynecologic oncology service. N=876 | ACS NSQIP risk calculator | Mortality |
| Tominaga 2016 ¹⁶⁰ | Patients over 70 years of age diagnosed with colorectal cancer and underwent curative colorectal resection from a single hospital. N=239 | E-PASS | Mortality • calibration |
| Tran Ba Loc 2010 ¹⁶¹ | Patients, at least 65 years old, undergoing major colorectal surgery. N=1186 | POSSUM P-POSSUM Surgical risk score | Mortality |
| Vather 2006 ¹⁶⁷ | Consecutive patients undergoing a major colorectal operation between January 2002 and October 2005 at the participating hospital. N=308 | POSSUM P-POSSUM | Mortality • c-statistic |
| Wang 2014 ¹⁶⁹ | Consecutive patients treated | POSSUM | Mortality |

| Study | Population | Risk tool | Outcomes |
|-----------------------------|--|---|---|
| | surgically in the study centre following a diagnosis of hilar cholangiocarcinoma. N=100 | P-POSSUM E-PASS | c-statistic calibration Complications c-statistic calibration E-PASS c-statistic calibration |
| Wang 2017 ¹⁷² | Geriatric patients (age>60 years) with isolated spinal stenosis who underwent lumbar surgery. N=242 | ACS-NSQIP risk calculator | Mortality • c-statistic |
| Wani 2005 ¹⁷³ | Patients of diagnosed calcular disease of biliary tract over an 18 month period. N=500 | POSSUM | Mortality |
| Wolters 2006 ¹⁷⁶ | Patients received an aorto-bi-iliac or an aroto-bifemoral graft due to arterial occlusive disease. N=107 | POSSUM ASA classification | Mortality |
| Yap 2018 ¹⁷⁷ | Patients aged 19 years and older admitted for preoperative evaluation and cardiopulmonary risk stratification before non-cardiac surgery. N=424 | ACS NSQIP risk calculator | Mortality • c-statistic |
| Zattoni 2019 ¹⁷⁹ | Patients over 70 years old undergoing emergency abdominal surgery under general anaesthesia. | ASA classification Charleston Comorbidity index | Mortality • c-statistic |

| | _ |
|-----|-------------------------|
| 1 | NICE 2 |
| 2 | 2019. |
| 3 | All right |
| 4 | ights reserved. |
| 5 | ved. |
| 700 | Subject to Notice of ri |

| Study | Population | Risk tool | Outcomes |
|-------|------------|-----------|----------|
| | N=110 | | |

See Appendix D:for full evidence tables.

Quality assessment of clinical studies included in the evidence review 1.4.4

1.1 Discrimination

Table 3: Clinical evidence profile

| | | | | | | | Concordance statistic (c-stat: | |
|-----------|---------------|--------|-------------------------|--------------------------|-------------------------|---------------------|--------------------------------|----------|
| Risk tool | No of studies | n | Risk of bias | Inconsistency | Indirectness | Imprecision | median, range) | Quality |
| Mortality | | | | | | | | |
| POSSUM | 9 | 2537 | Serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 82% (47-95) | Very low |
| P-POSSUM | 13 | 4848 | Serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 81% (56-94) | Very low |
| NSQIP | 8 | 241905 | No serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 83% (62-97) | Low |
| E-PASS | 1 | 100 | Serious risk of bias | No serious inconsistency | No serious indirectness | Serious imprecision | 84% | Low |
| ASA | 5 | 54174 | Serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 67% (59-80) | Very low |
| Charlson | 4 | 136995 | Serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 77% (58-86) | Very low |
| SORT | 1 | 78 | Serious risk of bias | No serious inconsistency | No serious indirectness | Serious imprecision | 80% | Low |
| SRS | 2 | 2916 | Serious risk of bias | Serious inconsistency | No serious indirectness | Serious imprecision | 72% | Very low |

| 1 | | |
|---|--|--|
| | | |
| | | |
| | | |

Concordance statistic (c-stat: **Risk tool** No of studies Risk of bias Inconsistency Indirectness Imprecision median, range) Quality (66-78)Morbidity (composite outcome) **POSSUM** 8 2556 Serious risk of Serious No serious Serious 73.5% Very low bias inconsistency indirectness imprecision (56-84)P-POSSUM 113 Serious risk of 61% 1 No serious No serious Cannot be Low bias inconsistency indirectness assessed Serious risk of Serious Very low **NSQIP** 8 4819 Serious No serious 62.5% bias inconsistency indirectness imprecision (55-88)E-PASS 3 1093 67% Serious risk of Serious Very low No serious Serious bias inconsistency indirectness imprecision (59-68)ASA 6 64033 Serious risk of Serious 65% Very low Serious No serious imprecision bias inconsistency indirectness (52-77)103357 Serious risk of Very low Charlson 4 Serious No serious Serious 64% bias inconsistency indirectness imprecision (56-69)GRADE was conducted with emphasis on c-statistic as this was the primary measures agreed for decision making

1.2 **Calibration**

| Risk tool | No of studies | n | Risk of bias | Inconsistency | Indirectness | Imprecision | Observed/Expected ratio (median, range) | Quality |
|-----------|---------------|---|--------------|---------------|--------------|-------------|---|---------|

a) Risk of bias was assessed using the PROBAST checklist. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

b) Inconsistency was assessed by visual inspection of a plotted summary of c-statistics and for overlap of confidence intervals where reported.

c) The judgement of precision was based on visual inspection of the confidence region of the c-statistic, where variation in confidence intervals was reported.

| | 000 |
|---------------------|-----------|
| 1 | |
| - 28 345 | 0 140 100 |
| | |

| Mortality | | | | | | | | |
|-------------------------------|---|------|----------------------|--------------------------|-------------------------|---------------|----------------------|----------|
| POSSUM | 7 | 4048 | Serious risk of bias | Serious inconsistency | No serious indirectness | not estimable | 0.86 (0-1.11) | Very low |
| P-POSSUM | 8 | 6853 | Serious risk of bias | Serious inconsistency | No serious indirectness | not estimable | 1.03 (0.68-15.87) | Very low |
| NSQIP | 4 | 2634 | Serious risk of bias | Serious inconsistency | No serious indirectness | not estimable | 1.23 (0.64-1.28) | Very low |
| E-PASS | 1 | 100 | Serious risk of bias | No serious inconsistency | No serious indirectness | not estimable | 1 | Low |
| ASA | 1 | 1186 | Serious risk of bias | No serious inconsistency | No serious indirectness | not estimable | 1.08 | Low |
| Morbidity (composite outcome) | | | | | | | | |
| POSSUM | 8 | 1915 | Serious risk of bias | Serious inconsistency | No serious indirectness | not estimable | 1.10 (0.8-1.44) | Very low |
| NSQIP | 5 | 3510 | Serious risk of bias | Serious inconsistency | No serious indirectness | not estimable | 1.06 (0.76-1.84) | Very low |

a) Risk of bias was assessed using the PROBAST checklist. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

b) Inconsistency was assessed by visual inspection of a plotted summary where reported.
c) The judgement of precision was not possible in the absence of the confidence region of the O/E ratio, summary ratios were downgraded due to this limitation.

1.3 Economic evidence

| 2 | 1.3.1 | Included studies |
|----------|-------|--|
| 3 | | No health economic studies were included. |
| 4 | 1.3.2 | Excluded studies |
| 5 6 | | No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations. |
| 7 | | See also the health economic study selection flow chart in Appendix H:. |
| 8 | | |
| 9 | 1.4 | Evidence statements |
| 0 | 1.4.1 | Clinical evidence statements |
| 2 | | Risk tools mortality concordance |
| 3 | | Nine studies reported an accuracy of 47-95% with POSSUM predicting mortality, with a median c-statistic of 82% (n=2537, Very low quality evidence) |
| 5 6 | | Thirteen studies reported an accuracy of 56-94% with P-POSSUM predicting mortality, with a median c-statistic of 81% (n=4848, Very low quality evidence) |
| 7 8 | | Eight studies reported an accuracy of 62-97% with NSQIP predicting mortality, with a median c-statistic of 83% (n=241905, Low quality evidence) |
| 9 20 | | One study reported an accuracy of 84% with E-PASS for predicting mortality (n=100, Low quality evidence) |
| 21 22 | | Five studies reported an accuracy of 59-80% with ASA for predicting mortality, with a median c-statistic of 67% (n=54174, Very low quality evidence) |
| 23 24 | | Four studies reported an accuracy of 58-86% with Charlson Comorbidity Index for predicting mortality, with a median c-statistic of 77% (n=136995, Very low quality evidence) |
| 25 26 | | One study reported an accuracy of 80% with SORT for predicting mortality (n=78, Very low quality evidence) |
| 27 28 | | Two studies reported an accuracy of 66-78% with SRS for predicting mortality of, with a median c-statistic of 72% (n=2916, Very low quality evidence) |
| 29 | | Risk tools morbidity concordance |
| 30 31 | | Eight studies reported an accuracy of 56-84% with POSSUM for predicting morbidity, with a median c-statistic of 73.5% (n=2556, Very low quality evidence) |
| 32 | | One study reported an accuracy of 61% with P-POSSUM for predicting morbidity (n=113, |

Low quality evidence)

| 1 2 | | Eight studies reported an accuracy of 55-88% with NSQIP for predicting morbidity, with a median c-statistic of 62.5% (n=4819, Very low quality evidence) |
|----------------------------|---------|---|
| 3 4 | | Three studies reported an accuracy of 59-68% with E-PASS for predicting morbidity, with a median c-statistic of 67% (n=1093, Very low quality evidence) |
| 5 6 | | Six studies reported an accuracy of 52-77% with ASA for predicting morbidity, with a median c-statistic of 65% (n=64033, Very low quality evidence) |
| 7 8 | | Four studies reported an accuracy of 56-69% with Charlson Comorbidity Index for predicting morbidity, with a median c-statistic of 64% (n=103357, Very low quality evidence) |
| 9 | | Risk tools mortality calibration |
| 10 11 | | Seven studies reported a predictive accuracy of POSSUM for mortality with median O/E ratio of 0.86 (n=4048, Very low quality evidence) |
| 12 13 | | Eight studies reported a predictive accuracy of P-POSSUM for mortality with median O/E ratio of 1.03 (n=6853, Very low quality evidence) |
| 14 15 | | Four studies reported a predictive accuracy of NSQIP for mortality with median O/E ratio of 1.23 (n=2634, Very low quality evidence) |
| 16 17 | | One study reported a predictive accuracy of E-PASS for mortality with median O/E ratio of 1 (n=100, Low quality evidence) |
| 18 19 | | One study reported a predictive accuracy of ASA for mortality with median O/E ratio of 1.08 (n=1186, Low quality evidence) |
| 20 | | Risk tools morbidity calibration |
| 21 22 | | Eight studies reported a predictive accuracy of POSSUM for morbidity with median O/E ratio of 1.10 (n=1915, Very low quality evidence) |
| 23 24 | | Five studies reported a predictive accuracy of NSQIP for morbidity with median O/E ratio of 1.06 (n=3510, Very low quality evidence) |
| 25 | 1.4.2 | Health economic evidence statements |
| 26 | | No relevant economic evaluations were identified. |
| 27 | 1.5 | The committee's discussion of the evidence |
| 28 | | Please see recommendation 1.3.1 in the guideline. |
| 29 | 1.5.1 | Interpreting the evidence |
| 30 | 1.5.1.1 | The outcomes that matter most |
| 31 32 33 34 35 | | The committee highlighted that a key goal of preoperative risk assessment is to identify and stratify those at increased risk of mortality and morbidity. As such, the main outcomes included in this evidence review was the predictive accuracy of risk tools, as measured by sensitivity, specificity, predictive values, c-statistic data, and predicted risk versus observed risk (calibration data). The risk prediction tools do not predict or report specific morbidities, |

rather morbidity rate as a composite outcome.

1 1.5.1.2 The quality of the evidence

The quality of evidence varied from low to very low. Studies were downgraded for risk of bias inconsistency and imprecision. Risk of bias was generally serious or very serious due to unclear methodology in terms of blinding of risk tool and outcome data. A large proportion of the available concordance data had no reported variance data (such as 95% CI). As such, many of the outcomes were downgraded for a subsequent risk of inconsistency and possible imprecision. Due to the method of reporting and analysis of the calibration data with observed/expected ratios, it was also not possible to ascertain variance data. These outcomes were subsequently downgraded due to the uncertainty around outcome precision.

10 1.5.1.3 Benefits and harms

The committee agreed that an accurate risk prediction tool can have benefits in directing discussions between clinicians about the appropriateness of the planned surgery and whether it should proceed as planned, should be abbreviated, or whether alternative nonsurgical options should be considered. Additionally, the committee suggested that being able to quantify morbidity risk allows planning for post-operative destination, discussions about recovery or convalescence and the anticipated clinical course. Effective risk tools can subsequently have a benefit on patient experience and postoperative quality of life. One possible disadvantage (harm) of using risk tools is underestimating mortality or morbidity risk, which may lead to insufficient attention to preventable risks, insufficient monitoring or surgery being performed when alternative options may be more appropriate. Another potential harm is over-estimating operative risk, which can lead to unnecessary over-vigilance and possibly reluctance on the part of the patient (and maybe clinician) to commence surgery. Thus using accurate risk prediction was seen by the GC as vital to maximise benefits and minimise harms.

The committee discussed the results and utility of the risk tools reviewed and agreed that a concordance (c-statistic) of >80% represents a good level of predictive accuracy, with results of >90% demonstrating an excellent test. The committee added that a test yielding <70% accuracy would be considered poor. The committee also noted that calibration data showing a test observed/expected ratio of 0.9-1.1 would be considered a fair level of accuracy, adding that it would be better to overestimate the event rate than to underestimate morbidity or mortality.

The committee agreed that tools such as P-POSSUM, NSQIP and E-PASS showed a fair level of accuracy for mortality with median c-statistic of ~85%. The committee agreed that ASA used as a risk tool showed a lower level of predictive accuracy with a median c-statistic of 67%. The committee highlighted though that there was notable inconsistency in the accuracy of tools in the prediction of mortality and morbidity, with most tools ranging from ~60% to ~90% accuracy for predicting mortality.

The committee noted that all tools were less accurate in predicting morbidity showing a predictive accuracy of ~60-70%, but agreed that this was expectedly lower than the accuracy in predicting mortality and could still be informative for a healthcare professional and patient scheduled to undergo surgery.

The committee agreed that the evidence on risk tool calibration showed significant inconsistency between studies, limiting the utility of these results. As such, the committee weighted the majority of their discussions on the benefits and harms of risk tools on the on risk tool concordance evidence.

The committee considered that the noted variation in results could be due to the heterogeneity in study populations, with included studies providing risk prediction for a range of varied types of surgery. This was a notable concern to the committee, and while they felt confident that risk tools can have a benefit in the preoperative setting in predicting morbidity and mortality, they were not able to determine which risk tool should be used.

1.5.2 Cost effectiveness and resource use

3 No economic evaluations were identified for this question.

All of the different risk tools are freely available, and therefore do not have a cost associated with using them. Although they require some time to complete, the committee stated it would usually take less than 5 minutes during a preoperative assessment. The different types of risk tools do require different information, for example, some require information on the adult's haemoglobin levels, however, all of these tests are already carried out as part of preoperative assessment.

The committee highlighted that if a risk tool is not accurate at estimating mortality and morbidity, then the wrong people may be given targeted interventions before surgery (incorrectly identified as high risk), or the wrong people may not be receiving interventions they should have (incorrectly identified as low risk). These targeted interventions vary, but could require being referred to a Consultant Anaesthetist, Cardiologist or Care of the Elderly specialist, or being admitted to a specialist area after surgery. Therefore, the committee highlighted the importance of accurately identifying who is at risk, as these downstream interventions can have a high cost associated with them, or quality of life could be lost from people not receiving interventions they require.

A recommendation was made to use a validated risk tool as part of a preoperative assessment. The committee agreed that the most commonly used tools such as P-POSSUM, NSQIP and E-PASS showed similar level of accuracy in predicting mortality and therefore will not lead to differences in the downstream interventions that are implemented in relation to patient risk. As current practice already involves using a validated risk tool as part of a preoperative assessment, the recommendation will not have a substantial resource impact.

1.5.3 Other factors the committee took into account

The committee noted that a validated risk stratification tool can also help to frame discussions about risk with the person having surgery as well as the wider perioperative team on the impact of surgical management on overall outcome. They agreed that the risk of postoperative morbidity is an important concern for people when they are making decisions about surgery. The committee noted that the recommendation was applicable to people undergoing dental surgery.

The committee considered that the findings of risk tools could have an influence over allocation of resources, although this would not be solely based on the risk tool findings, but alongside clinical assessment and judgement.

References

- 1. Ahle SL, Healy JM, Pei KY. Prediction of postoperative surgical risk: a needs assessment for a medical student curriculum. Journal of Surgical Education. 2019; 76(1):89-92
 - 2. Al-Homoud S, Purkayastha S, Aziz O, Smith JJ, Thompson MD, Darzi AW et al. Evaluating operative risk in colorectal cancer surgery: ASA and POSSUM-based predictive models. Surgical Oncology. 2004; 13(2-3):83-92
 - 3. Ali R, Schwalb JM, Nerenz DR, Antoine HJ, Rubinfeld I. Use of the modified frailty index to predict 30-day morbidity and mortality from spine surgery. Journal of Neurosurgery Spine. 2016; 25(4):537-541
 - 4. Amrock LG, Neuman MD, Lin HM, Deiner S. Can routine preoperative data predict adverse outcomes in the elderly? Development and validation of a simple risk model incorporating a chart-derived frailty score. Journal of the American College of Surgeons. 2014; 219(4):684-694
 - 5. Anderson JE, Lassiter R, Bickler SW, Talamini MA, Chang DC. Brief tool to measure risk-adjusted surgical outcomes in resource-limited hospitals. Archives of Surgery. 2012; 147(9):798-803
 - Anonymous. Correction: Preoperative risk score for the prediction of mortality after repair of ruptured abdominal aortic aneurysms (Journal of Vascular Surgery (2018) 68(4) (991-997), (S0741521418302751)(10.1016/j.jvs.2017.12.075)). Journal of Vascular Surgery. 2018; 68(5):1623
 - 7. Anonymous. Development of machine learning algorithms for prediction of discharge disposition after elective inpatient surgery for lumbar degenerative disc disorders. Neurosurgical Focus. 2018; 45(5):E6
 - 8. Arakkal D, Prabhu P, Evans M, Hoddnett D, Tailor A, Butler-Manuel S et al. Corelation between the ACS and p Possum Calculator to improve patient understanding of the risk of postoperative morbidity and mortality. BJOG: An International Journal of Obstetrics and Gynaecology. 2018; 125(Suppl 1):157
 - 9. Armstrong BN, Renson A, Zhao LC, Bjurlin MA. Development of novel prognostic models for predicting complications of urethroplasty. World Journal of Urology. 2019; 37(3):553-559
 - 10. Arshad W, Longbotham D, Kaur G. Is P POSSUM better than anaesthetic/surgical assessment in risk stratification of the major surgical patient? Colorectal Disease. 2014; 2):123
 - 11. Baker S, Waldrop MG, Swords J, Wang T, Heslin M, Contreras C et al. Timed stairclimbing as a surrogate marker for sarcopenia measurements in predicting surgical outcomes. Journal of Gastrointestinal Surgery. 2018; Epublication
 - 12. Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery. 2014; 156(2):298-304
- 42 13. Bekelis K, Desai A, Bakhoum SF, Missios S. A predictive model of complications after 43 spine surgery: the National Surgical Quality Improvement Program (NSQIP) 2005-44 2010. Spine Journal. 2014; 14(7):1247-55

- 1 14. Bennett-Guerrero E, Hyam JA, Shaefi S, Prytherch DR, Sutton GL, Weaver PC et al. Comparison of P-POSSUM risk-adjusted mortality rates after surgery between patients in the USA and the UK. British Journal of Surgery. 2003; 90(12):1593-8
 - 15. Bihorac A, Ozrazgat-Baslanti T, Ebadi A, Motaei A, Madkour M, Pardalos PM et al. MySurgeryRisk: Development and validation of a machine-learning risk algorithm for major complications and death after surgery. Annals of Surgery. 2019; 269(4):652-662
 - 16. Blair B, Lehman E, Jafri S, Raman J. Actual versus estimated clinical outcomes using the ACS surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma. Journal of Urology. 2016; 195(4 Suppl):e943
 - 17. Blair BM, Lehman EB, Jafri SM, Kaag MG, Raman JD. Predicted versus observed 30-day perioperative outcomes using the ACS NSQIP surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma. International Urology and Nephrology. 2018; 50(7):1249-1256
 - 18. Bodea R, Hajjar NA, Bartos A, Zaharie F, Graur F, Iancu C. Evaluation of P-POSSUM risk scoring system in prediction of morbidity and mortality after pancreaticoduodenectomy. Chirurgia. 2018; 113(3):399-404
 - 19. Bollschweiler E, Lubke T, Monig SP, Holscher AH. Evaluation of POSSUM scoring system in patients with gastric cancer undergoing D2-gastrectomy. BMC Surgery. 2005; 5:8
 - 20. Bonaventura A, Leale I, Carbone F, Liberale L, Dallegri F, Montecucco F et al. Presurgery age-adjusted Charlson Comorbidity Index is associated with worse outcomes in acute cholecystitis. Digestive and Liver Disease. 2019; 51(6):858-863
 - 21. Borja-Cacho D, Parsons HM, Habermann EB, Rothenberger DA, Henderson WG, Al-Refaie WB. Assessment of ACS NSQIP's predictive ability for adverse events after major cancer surgery. Annals of Surgical Oncology. 2010; 17(9):2274-2282
 - 22. Boyd SS, O'Sullivan DM, Lasala C. Evaluating Postoperative Morbidity in Patients Undergoing Pelvic Reconstructive Surgery Using the American College of Surgeons national surgical quality improvement program surgical risk calculator. Female Pelvic Medicine & Reconstructive Surgery. 2019; Epublication
 - 23. Brennan M, Puri S, Ozrazgat-Baslanti T, Feng Z, Ruppert M, Hashemighouchani H et al. Comparing clinical judgment with the MySurgeryRisk algorithm for preoperative risk assessment: A pilot usability study. Surgery. 2019; 165(5):1035-1045
 - 24. Bronheim RS, Oermann EK, Bronheim DS, Caridi JM. Revised Cardiac Risk Index versus ASA Status as a predictor for noncardiac events after posterior lumbar decompression. World Neurosurgery. 2018; 120:e1175-e1184
 - 25. Bryce GJ, Payne CJ, Gibson SC, Kingsmore DB, Byrne DS, Delles C. Risk stratification scores in elective open abdominal aortic aneurysm repair: are they suitable for preoperative decision making? European Journal of Vascular and Endovascular Surgery. 2012; 44(1):55-61
 - 26. Bulow E, Cnudde P, Rogmark C, Rolfson O, Nemes S. Low predictive power of comorbidity indices identified for mortality after acute arthroplasty surgery undertaken for femoral neck fracture. Bone & Joint Journal. 2019; 101-B(1):104-112
 - 27. Burg ML, Clifford TG, Bazargani ST, Lin-Brande M, Miranda G, Cai J et al. Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments. Urologic Oncology. 2019; 37(1):40-47

- Burgess JR, Smith B, Britt R, Weireter L, Polk T. Predicting postoperative complications for acute care surgery patients using the ACS NSQIP surgical risk calculator. American Surgeon. 2017; 83(7):733-738
 - 29. Butterfield R, Stedman W, Herod R, Aneman A. Does adding ICU data to the POSSUM score improve the prediction of outcomes following surgery for upper gastrointestinal malignancies? Anaesthesia and Intensive Care. 2015; 43(4):490-6
 - 30. Cao A, Khayat S, Cash E, Nickel C, Gettelfinger J, Tennant P et al. ACS NSQIP risk calculator reliability in head and neck oncology: The effect of prior chemoradiation on NSQIP risk estimates following laryngectomy. American Journal of Otolaryngology. 2018; 39(2):192-196
 - 31. Cengiz F, Kamer E, Zengel B, Uyar B, Tavusbay C, Unalp HR. Comparison of different scoring systems in patients undergoing colorectal cancer surgery for predicting mortality and morbidity. Indian Journal of Cancer. 2014; 51(4):543-8
 - 32. Chun DH, Kim DY, Choi SK, Shin DA, Ha Y, Kim KN et al. Feasibility of a modified E-PASS and POSSUM system for postoperative risk assessment in patients with spinal disease. World Neurosurgery. 2018; 112:e95-e102
 - 33. Chung PJ, Lee JS, Tam S, Schwartzman A, Bernstein MO, Dresner L et al. Predicting 30-day postoperative mortality for emergent anterior abdominal wall hernia repairs using the American College of Surgeons National Surgical Quality Improvement Program database. Hernia. 2017; 21(3):323-333
 - 34. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American College of Surgeons National Surgery Quality Improvement Program: morbidity and mortality risk calculator for colorectal surgery. Journal of the American College of Surgeons. 2009; 208(6):1009-1016
 - 35. Collard MK, Moszkowicz D, Clause-Verdreau AC, Beauchet A, Cudennec T, Vychnevskaia K et al. Postoperative morbidity and mortality for malignant colon obstruction: the American College of Surgeon calculator reliability. Journal of Surgical Research. 2018; 226:112-121
 - 36. Cologne KG, Keller DS, Liwanag L, Devaraj B, Senagore AJ. Use of the American College of Surgeons NSQIP surgical risk calculator for laparoscopic colectomy: how good is it and how can we improve it? Journal of the American College of Surgeons. 2015; 220(3):281-286
 - 37. Cote DJ, Dasenbrock HH, Gormley WB, Smith TR, Dunn IF. Adverse events after microvascular decompression: A national surgical quality improvement program analysis. World Neurosurgery. 2019; 128:e884-894
 - 38. Dahlke AR, Merkow RP, Chung JW, Kinnier CV, Cohen ME, Sohn MW et al. Comparison of postoperative complication risk prediction approaches based on factors known preoperatively to surgeons versus patients. Surgery. 2014; 156(1):39-45
 - 39. de Castro SM, Houwert JT, Lagarde SM, Reitsma JB, Busch OR, van Gulik TM et al. Evaluation of POSSUM for patients undergoing pancreatoduodenectomy. World Journal of Surgery. 2009; 33(7):1481-7
 - 40. Debinska I, Smolinska K, Osiniak J, Paluszkiewicz P. The possum scoring system and complete blood count in the prediction of complications after pancreato-duodenal area resections. Polski Przeglad Chirurgiczny. 2011; 83(1):10-8
 - 41. DeLuzio MR, Keshava HB, Wang Z, Boffa DJ, Detterbeck FC, Kim AW. A model for predicting prolonged length of stay in patients undergoing anatomical lung resection:

- a National Surgical Quality Improvement Program (NSQIP) database study. Interactive Cardiovascular and Thoracic Surgery. 2016; 23(2):208-15
 - 42. Dunn CP, Emeasoba EU, Holtzman AJ, Hung M, Kaminetsky J, Alani O et al. Comparing the predictive power of preoperative risk assessment tools to best predict major adverse cardiac events in kidney transplant patients. Surgery Research & Practice Print. 2019; 2019:9080856
 - 43. Dutta S, Al-Mrabt NM, Fullarton GM, Horgan PG, McMillan DC. A comparison of POSSUM and GPS models in the prediction of post-operative outcome in patients undergoing oesophago-gastric cancer resection. Annals of Surgical Oncology. 2011; 18(10):2808-17
 - 44. Easterlin MC, Chang DC, Wilson SE. A practical index to predict 30-day mortality after major amputation. Annals of Vascular Surgery. 2013; 27(7):909-17
 - 45. Egberts F, Hartje C, Schafmayer C, Kaehler KC, von Schonfels W, Hauschild A et al. Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM. Annals of the Royal College of Surgeons of England. 2011; 93(7):514-22
 - 46. Egberts JH, Stroeh A, Alkatout I, Goumas FA, Brand PA, Schafmayer C et al. Preoperative risk evaluation of postoperative morbidity in IBD patients--impact of the POSSUM score. International Journal of Colorectal Disease. 2011; 26(6):783-92
 - 47. Engin A, Engin AB, Kurukahvecioglu O, Sepici-Dincel A. Perioperative mortality prediction using possum in patients with gastrointestinal tumors: Do immunological variables affect individual predictive mortality risk? Pteridines. 2018; 29(1):114-123
 - 48. Farhat JS, Falvo AJ, Horst HM, Swartz A, Velanovich V, Patton JH et al. Are the frail destined to fail?: Frailty index as a predictor of surgical morbidity and mortality in the elderly. Journal of Trauma and Acute Care Surgery. 2012; 72(6):1526-1531
 - 49. Filip B, Hutanu I, Radu I, Anitei MG, Scripcariu V. Assessment of different prognostic scores for early postoperative outcomes after esophagectomy. Chirurgia. 2014; 109(4):480-5
 - 50. Ford J, Coughlin KR, Van Dorp D, Berri RN. Validation of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) risk calculator to estimate serious complications in patients undergoing major gastrointestinal oncologic resection. Journal of the American College of Surgeons. 2015; 221(4):e135-e136
 - 51. Fryer S, McCann J. ICNARC score versus P-POSSUM score for predicting mortality in emergency laparotomies. Journal of the Intensive Care Society. 2018; 19 (2 Suppl 1):129-130
 - 52. Fu MC, Ondeck NT, Nwachukwu BU, Garcia GH, Gulotta LV, Verma NN et al. What associations exist between comorbidity indices and postoperative adverse events after total shoulder arthroplasty? Clinical Orthopaedics and Related Research. 2019; 477(4):881-890
 - 53. Gentry RD, Dineen HA, Hahn JC. An overview of risk stratification in the elderly orthopaedic population. Current Geriatrics Reports. 2018; 7(2):92-102
 - 54. Golan S, Adamsky MA, Johnson SC, Barashi NS, Smith ZL, Rodriguez MV et al. National Surgical Quality Improvement Program surgical risk calculator poorly predicts complications in patients undergoing radical cystectomy with urinary diversion. Urologic Oncology. 2018; 36(2):77.e1-77.e7

- Hacohen Solovitz A, Ivry S, Ronen O. Man against the machine Differences in surgical risk evaluation. A cohort prospective study. International Journal of Surgery. 2018; 60:252-256
 - 56. Harris AHS, Kuo AC, Weng Y, Trickey AW, Bowe T, Giori NJ. Can machine learning methods produce accurate and easy-to-use prediction models of 30-day complications and mortality after knee or hip arthroplasty? Clinical Orthopaedics and Related Research. 2019; 477(2):452-460
 - 57. Hirose J, Taniwaki T, Fujimoto T, Okada T, Nakamura T, Okamoto N et al. Predictive value of E-PASS and POSSUM systems for postoperative risk assessment of spinal surgery. Journal of Neurosurgery Spine. 2014; 20(1):75-82
 - 58. Hirose J, Taniwaki T, Fujimoto T, Okada T, Nakamura T, Usuku K et al. Validity of epass system for postoperative morbidity of spinal surgery. Journal of Spinal Disorders & Techniques. 2015; 28(10):E595-E600
 - 59. Hirpara DH, Kidane B, Rogalla P, Cypel M, de Perrot M, Keshavjee S et al. Frailty assessment prior to thoracic surgery for lung or esophageal cancer: a feasibility study. Supportive Care in Cancer. 2019; 27(4):1535-1540
 - 60. Hobson SA, Sutton CD, Garcea G, Thomas WM. Prospective comparison of POSSUM and P-POSSUM with clinical assessment of mortality following emergency surgery. Acta Anaesthesiologica Scandinavica. 2007; 51(1):94-100
 - 61. Hoeks SE, Scholte op Reimer WJ, van Gestel YR, Smolderen KG, Verhagen H, van Domburg RT et al. Preoperative cardiac risk index predicts long-term mortality and health status. American Journal of Medicine. 2009; 122(6):559-65
 - 62. Hoftman N, Prunean A, Dhillon A, Danovitch GM, Lee MS, Gritsch HA. Revised Cardiac Risk Index (RCRI) is a useful tool for evaluation of perioperative cardiac morbidity in kidney transplant recipients. Transplantation. 2013; 96(7):639-43
 - 63. Huang J, Yuan Y, Wang Y, Chen Y, Kong W, Xue W et al. Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urologic Oncology. 2017; 35(12):671.e1-671.e9
 - 64. Huisman MG, van Leeuwen BL, Ugolini G, Montroni I, Spiliotis J, Stabilini C et al. "Timed Up & Go": a screening tool for predicting 30-day morbidity in onco-geriatric surgical patients? A multicenter cohort study. PloS One. 2014; 9(1):e86863
 - 65. Igari K, Ochiai T, Yamazaki S. POSSUM and P-POSSUM for risk assessment in general surgery in the elderly. Hepato-Gastroenterology. 2013; 60(126):1320-7
 - 66. Inoue K, Ueno T, Akishige N, Soeta T, Tsuchiya T, Nakayama S et al. Short-term outcomes of laparoscopic colorectal cancer surgery in elderly patients. -Is it really safe in elderly patients with severe comorbidities? International Journal of Surgery Open. 2019; 17:27-32
 - 67. Jean RA, DeLuzio MR, Kraev AI, Wang G, Boffa DJ, Detterbeck FC et al. Analyzing risk factors for morbidity and mortality after lung resection for lung cancer using the NSQIP database. Journal of the American College of Surgeons. 2016; 222(6):992-1000
- 43 68. Jensen AM, Crandall ML, Tepas JJ, 3rd, Ra JH. ACS NSQIP Surgical Risk
 44 Calculator: Pilot analysis on feasibility in an academic safety net hospital. Journal of
 45 Surgical Research. 2019; 236:124-128

- Kalender M, Adademir T, Tasar M, Ecevit AN, Karaca OG, Salihi S et al. Validation of EuroSCORE II risk model for coronary artery bypass surgery in high-risk patients.
 Kardiochirurgia I Torakochirurgia Polska. 2014; 11(3):252-6
 - 70. Kapma M, Kahmann O, van Stijn I, Zeebregts CJ, Vahl A. Evaluation of risk prediction models, V-POSSUM and GAS, in patients with acute abdominal aortic rupture treated with EVAR or an open procedure. Journal of Cardiovascular Surgery. 2017; 58(3):439-445
 - 71. Karabulut H, Toraman F, Alhan C, Camur G, Evrenkaya S, Dagdelen S et al. EuroSCORE overestimates the cardiac operative risk. Cardiovascular Surgery. 2003; 11(4):295-8
 - 72. Katlic MR, Coleman J, Khan K, Wozniak SE, Abraham JH. Sinai abbreviated geriatric evaluation: Development and validation of a practical test. Annals of Surgery. 2019; 269(1):177-183
 - 73. Kavanagh JW, Blyth C. An audit of 30-day fractured neck of femur mortality compared to predictions from possum, p-possum and the Nottingham Hip Fracture Score (NHFS) at a district general hospital in the UK-are pre-operative risk scores relevant to the individual? Journal of the American Geriatrics Society. 2016; 64(S1):S83
 - 74. Kelly KJ, Greenblatt DY, Wan Y, Rettammel RJ, Winslow E, Cho CS et al. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. Journal of Gastrointestinal Surgery. 2011; 15(2):250-259
 - 75. Kertai MD, Steyerberg EW, Boersma E, Bax JJ, Vergouwe Y, van Urk H et al. Validation of two risk models for perioperative mortality in patients undergoing elective abdominal aortic aneurysm surgery. Vascular and Endovascular Surgery. 2003; 37(1):13-21
 - 76. Khalfallah M, Jerraya H, Sbai A, Dougaz W, Changuel A, Nouira R et al. Prognostic Nutritional Index score is useful to predict post-operative mortality and morbidity in gastric cancer. Tunisie Medicale. 2016; 94(7):401-405
 - 77. Khene ZE, Peyronnet B, Freton L, Graffeille V, Pradere B, Robert C et al. What is better for predicting morbidity of robotic partial nephrectomy-a score or your clinical judgement? European Urology Focus. 2018; Epublication
 - 78. Kim CY, Sivasundaram L, LaBelle MW, Trivedi NN, Liu RW, Gillespie RJ. Predicting adverse events, length of stay, and discharge disposition following shoulder arthroplasty: a comparison of the Elixhauser Comorbidity Measure and Charlson Comorbidity Index. Journal of Shoulder and Elbow Surgery. 2018; 27(10):1748-1755
 - 79. Klausing A, Martini M, Wimmer MD, Gravius S, Wirtz DC, Randau TM. Postoperative medical complications and intermediate care unit/intensive care unit admission in joint replacement surgery: A prospective risk model. Journal of Arthroplasty. 2019; 34(4):717-722
 - 80. Klinceva M, Widimsky P, Dohnalova A. Prospective use of EuroSCORE for the short-term risk evaluation of consecutive cardiac surgery candidates: are there any differences in prediction of perioperative risk versus risk of nonsurgical treatments? Vnitrni Lekarstvi. 2006; 52(12):1156-61
 - 81. Knight B, Sherlock D, Manu M, D OR. Outcome predictors after major pancreatic surgery; The role of possum, p-POSSUM and the Glasgow prognostic score. Pancreatology. 2009; 9(4):476

- Kong CH, Guest GD, Stupart DA, Faragher IG, Chan ST, Watters DA. Recalibration and validation of a preoperative risk prediction model for mortality in major colorectal surgery. Diseases of the Colon and Rectum. 2013; 56(7):844-9
 - 83. Kong CH, Guest GD, Stupart DA, Faragher IG, Chan ST, Watters DA. Colorectal preOperative Surgical Score (CrOSS) for mortality in major colorectal surgery. ANZ Journal of Surgery. 2015; 85(6):403-7
 - 84. Kongkaewpaisan N, Lee JM, Eid AI, Kongwibulwut M, Han K, King D et al. Can the emergency surgery score (ESS) be used as a triage tool predicting the postoperative need for an ICU admission? American Journal of Surgery. 2019; 217(1):24-28
 - 85. Kongwibulwut M, Chiang K, Lee JM, Eid AI, Kongkaewpaisan N, Han K et al. Life after 90: Predictors of mortality and performance of the ACS-NSQIP risk calculator in 4,724 nonagenarian patients undergoing emergency general surgery. Journal of Trauma and Acute Care Surgery. 2019; 86(5):853-857
 - 86. Kurki TS, Kataja MJ, Reich DL. Validation of a preoperative risk index as a predictor of perioperative morbidity and hospital costs in coronary artery bypass graft surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2002; 16(4):401-4
 - 87. Kwok AC, Lipsitz SR, Bader AM, Gawande AA. Are targeted preoperative risk prediction tools more powerful? A test of models for emergency colon surgery in the very elderly. Journal of the American College of Surgeons. 2011; 213(2):220-225
 - 88. Lakomkin N, Zuckerman SL, Stannard B, Montejo J, Sussman ES, Virojanapa J et al. Preoperative risk stratification in spine tumor surgery a comparison of the modified Charlson Index, Frailty Index, and ASA score. Spine. 2018; 44(13):E782-787
 - 89. Lam CM, Fan ST, Yuen AW, Law WL, Poon K. Validation of POSSUM scoring systems for audit of major hepatectomy. British Journal of Surgery. 2004; 91(4):450-4
 - 90. Laurent M, Fournet M, Feit B, Oger E, Donal E, Thebault C et al. Simple bedside clinical evaluation versus established scores in the estimation of operative risk in valve replacement for severe aortic stenosis. Archives of Cardiovascular Diseases. 2013; 106(12):651-60
 - 91. Lazarides MK, Arvanitis DP, Drista H, Staramos DN, Dayantas JN. POSSUM and APACHE II scores do not predict the outcome of ruptured infrarenal aortic aneurysms. Annals of Vascular Surgery. 1997; 11(2):155-8
 - 92. Le Manach Y, Collins G, Rodseth R, Le Bihan-Benjamin C, Biccard B, Riou B et al. Preoperative score to predict postoperative mortality (pospom): Derivation and validation. Anesthesiology. 2016; 124(3):570-9
 - 93. Lee SG, Russ A. Predicting and preventing postoperative outcomes. Clinics in Colon and Rectal Surgery. 2019; 32(3):149-156
 - 94. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100(10):1043-9
 - 95. Lima MJM, Cristelo DFM, Mourao JB. Physiological and operative severity score for the enumeration of mortality and morbidity, frailty, and perioperative quality of life in the elderly. Saudi Journal of Anaesthesia. 2019; 13(1):3-8
 - 96. Lindroth H, Bratzke L, Twadell S, Rowley P, Kildow J, Danner M et al. Predicting postoperative delirium severity in older adults: The role of surgical risk and executive function. International Journal of Geriatric Psychiatry. 2019; 34(7):1018-1028

- Malik AT, Quatman CE, Phieffer LS, Jain N, Khan SN, Ly TV. 30-day adverse events, length of stay and re-admissions following surgical management of pelvic/acetabular fractures. Journal of Clinical Orthopaedics and Trauma. 2019; Epublication
 - 98. Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A et al. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology. 2018; 01:01
 - 99. Markovic D, Jevtovic-Stoimenov T, Stojanovic M, Vukovic A, Dinic V, Markovic-Zivkovic B et al. Addition of clinical risk scores improves prediction performance of American Society of Anesthesiologists (ASA) physical status classification for postoperative mortality in older patients: a pilot study. European Geriatric Medicine. 2018; 9(1):51-59
 - 100. Marufu TC, Mannings A, Moppett IK. Risk scoring models for predicting peri-operative morbidity and mortality in people with fragility hip fractures: Qualitative systematic review. Injury. 2015; 46(12):2325-34
 - 101. Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status historical perspectives and modern developments. Anaesthesia. 2019; 74(3):373-379
 - 102. Meguid RA, Bronsert MR, Juarez-Colunga E, Hammermeister KE, Henderson WG. Surgical risk preoperative assessment system (SURPAS): II. Parsimonious risk models for postoperative adverse outcomes addressing need for laboratory variables and surgeon specialty-specific models. Annals of Surgery. 2016; 264(1):10-22
 - 103. Meguid RA, Bronsert MR, Juarez-Colunga E, Hammermeister KE, Henderson WG. Surgical risk preoperative assessment system (SURPAS): III. accurate preoperative prediction of 8 adverse outcomes using 8 predictor variables. Annals of Surgery. 2016; 264(1):23-31
 - 104. Nag DS. Assessing the risk: Scoring systems for outcome prediction in emergency laparotomies. Biomedicine. 2015; 5(4):20
 - 105. Nagashima I, Takada T, Okinaga K, Nagawa H. A scoring system for the assessment of the risk of mortality after partial hepatectomy in patients with chronic liver dysfunction. Journal of Hepato-Biliary-Pancreatic Surgery. 2005; 12(1):44-8
 - 106. Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL et al. Validation of European system for cardiac operative risk evaluation (EuroSCORE) in North American cardiac surgery. European Journal of Cardio-Thoracic Surgery. 2002; 22(1):101-5
 - 107. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). European Journal of Cardio-Thoracic Surgery. 1999; 16(1):9-13
 - 108. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual, updated 2018. London. National Institute for Health and Care Excellence, 2014. Available from: https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview
 - 109. Nesi F, Leo E, Biancari F, Bartolucci R, Rainio P, Satta J et al. Preoperative risk stratification in patients undergoing elective infrarenal aortic aneurysm surgery: evaluation of five risk scoring methods. European Journal of Vascular and Endovascular Surgery. 2004; 28(1):52-8
 - 110. Ngulube A, Muguti GI, Muguti EG. Validation of POSSUM, P-POSSUM and the surgical risk scale in major general surgical operations in Harare: A prospective observational study. Annals of Medicine & Surgery. 2019; 41:33-39

- 1 111. O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Annals of Thoracic Surgery. 2009; 88(1 Suppl):S23-42
 - 112. Parmar CD, Torella F. Prediction of major adverse cardiac events in vascular surgery: are cardiac risk scores of any practical value? Vascular and Endovascular Surgery. 2010; 44(1):14-9
 - 113. Patila T, Kukkonen S, Vento A, Pettila V, Suojaranta-Ylinen R. Relation of the Sequential Organ Failure Assessment score to morbidity and mortality after cardiac surgery. Annals of Thoracic Surgery. 2006; 82(6):2072-8
 - 114. Patterson BO, Holt PJ, Hinchliffe R, Loftus IM, Thompson MM. Predicting risk in elective abdominal aortic aneurysm repair: a systematic review of current evidence. European Journal of Vascular and Endovascular Surgery. 2008; 36(6):637-45
 - 115. Paul M, Raz A, Leibovici L, Madar H, Holinger R, Rubinovitch B. Sternal wound infection after coronary artery bypass graft surgery: validation of existing risk scores. Journal of Thoracic and Cardiovascular Surgery. 2007; 133(2):397-403
 - 116. Pavone C, Candela L, Fontana D, Simonato A. Postoperative complications and 90-day mortality in radical cystectomy in high-risk patients: A monocentric retrospective observational study. Urologia (Treviso). 2018; 85(3):111-117
 - 117. Perkins J. The MELD score as a predictor of nontransplant surgical mortality in patients with cirrhosis. Liver Transplantation. 2006; 12(1):159
 - 118. Perkins L, Jeffries M, Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clinical Gastroenterology and Hepatology. 2004; 2(12):1123-8
 - 119. Pillai BS, Baloria KA, Selot N. Validation of the European System for Cardiac Operative Risk Evaluation-II model in an urban Indian population and comparison with three other risk scoring systems. Annals of Cardiac Anaesthesia. 2015; 18(3):335-42
 - 120. Pinna-Pintor P, Bobbio M, Colangelo S, Veglia F, Giammaria M, Cuni D et al. Inaccuracy of four coronary surgery risk-adjusted models to predict mortality in individual patients. European Journal of Cardio-Thoracic Surgery. 2002; 21(2):199-204
 - 121. Pliam MB, Shaw RE, Zapolanski A. Comparative analysis of coronary surgery risk stratification models. Journal of Invasive Cardiology. 1997; 9(3):203-222
 - 122. Prabakaran V, Thangaraju T, Mathew AC, Govindan V, Kannan V, Poulose TR. CR-Possum-Can it be used to predict morbidity? A single-centre retrospective study. Indian Journal of Surgical Oncology. 2019; 10(1):174-179
 - 123. Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Accuracy, calibration and clinical performance of the EuroSCORE: can we reduce the number of variables? European Journal of Cardio-Thoracic Surgery. 2010; 37(3):724-9
 - 124. Ranucci M, Di Dedda U, Castelvecchio S, La Rovere MT, Menicanti L, Surgical Clinical Outcome Research Group. In search of the ideal risk-scoring system for very high-risk cardiac surgical patients: a two-stage approach. Journal of Cardiothoracic Surgery. 2016; Epublication
- 44 125. Ranucci M, Pistuddi V, Scolletta S, de Vincentiis C, Menicanti L. The ACEF II Risk 45 Score for cardiac surgery: updated but still parsimonious. European Heart Journal. 46 2018; 39(23):2183-2189

- 1 126. Rasmussen M, Platell C, Jones M. Monitoring excess unplanned return to theatre following colorectal cancer surgery. ANZ Journal of Surgery. 2018; 88(11):1168-1173
 - 127. Raymond BL, Wanderer JP, Hawkins AT, Geiger TM, Ehrenfeld JM, Stokes JW et al. Use of the American College of Surgeons national surgical quality improvement program surgical risk calculator during preoperative risk discussion: The patient perspective. Anesthesia and Analgesia. 2019; 128(4):643-650
 - 128. Reis P, Lopes AI, Leite D, Moreira J, Mendes L, Ferraz S et al. Predicting mortality in patients admitted to the intensive care unit after open vascular surgery. Surgery Today. 2019; 49(10):836-842
 - 129. Rivard C, Nahum R, Slagle E, Duininck M, Isaksson Vogel R, Teoh D. Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy. Gynecologic Oncology. 2016; 141(2):281-286
 - 130. Rix TE, Bates T. Pre-operative risk scores for the prediction of outcome in elderly people who require emergency surgery. World Journal of Emergency Surgery. 2007; 2:16
 - 131. Roxas MFT, Castro EJT. Validating the American College of Surgeons (ACS)-NSQIP surgical risk calculator in a Philippine ACS-NSQIP hospital collaboration. Journal of the American College of Surgeons. 2017; 225 (4 Suppl 2):e23-e24
 - 132. Ryan SP, Politzer C, Green C, Wellman S, Bolognesi M, Seyler T. Albumin versus American Society of Anesthesiologists score: Which is more predictive of complications following total joint arthroplasty? Orthopedics. 2018; 41(6):354-362
 - 133. Saafan T, El Ansari W, Al-Yahri O, Eleter A, Eljohary H, Alfkey R et al. Assessment of PULP score in predicting 30-day perforated duodenal ulcer morbidity, and comparison of its performance with Boey and ASA, a retrospective study. Annals of Medicine and Surgery. 2019; 42:23-28
 - 134. Sankar A, Beattie WS, Tait G, Wijeysundera DN. Evaluation of validity of the STOP-BANG questionnaire in major elective noncardiac surgery. British Journal of Anaesthesia. 2019; 122(2):255-262
 - 135. Saunders ND, Kearney JF, Lyon EH, Bloomston M, Squires MH, Kooby DA et al. The ACS-NSQIP surgical risk calculator lacks enough sensitivity to risk stratify patients with gastric cancer at academic medical centers. Annals of Surgical Oncology. 2015; 22(1):S136
 - 136. Schneider AL, Deig CR, Prasad KG, Nelson BG, Mantravadi AV, Brigance JS et al. Ability of the National Surgical Quality Improvement Program Risk Calculator to predict complications following total laryngectomy. JAMA Otolaryngology Head & Neck Surgery. 2016; 142(10):972-979
 - 137. Sfoungaristos S, Gofrit ON, Yutkin V, Landau EH, Pode D, Duvdevani M. External validation of CROES nephrolithometry as a preoperative predictive system for percutaneous nephrolithotomy outcomes. Journal of Urology. 2016; 195(2):372-6
 - 138. Sfoungaristos S, Lorber A, Gofrit ON, Yutkin V, Landau EH, Pode D et al. External validation and predictive accuracy assessment of guy's stone score as a preoperative tool for estimating percutaneous nephrolithotomy outcomes. Journal of Endourology. 2015; 29(10):1131-1135
- 44 139. Shah R, Velanovich V, Syed Z, Swartz A, Rubinfeld I. Limitations of patient-45 associated co-morbidity model in predicting postoperative morbidity and mortality in 46 pancreatic operations. Journal of Gastrointestinal Surgery. 2012; 16(5):986-92

- 1 140. Shaker S, Rivard C, Nahum R, Vogel RI, Teoh D. The American College of Surgeon's surgical risk calculator's ability to predict disposition in older gynecologic oncology patients undergoing laparotomy. Journal of Geriatric Oncology. 2019; 10(4):618-622
 - 141. Sharma A, Tanenbaum JE, Hogue O, Mehdi S, Vallabh S, Hu E et al. Predicting clinical outcomes following surgical correction of adult spinal deformity. Neurosurgery. 2019; 84(3):733-740
 - 142. Sharrock AE, McLachlan J, Chambers R, Bailey IS, Kirkby-Bott J. Emergency abdominal surgery in the elderly: Can we predict mortality? World Journal of Surgery. 2017; 41(2):402-409
 - 143. Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K et al. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Research. 2013; 33(6):2715-21
 - 144. Silaschi M, Conradi L, Seiffert M, Schnabel R, Schon G, Blankenberg S et al. Predicting risk in transcatheter aortic valve implantation: Comparative analysis of EuroSCORE II and established risk stratification tools. Thoracic and Cardiovascular Surgeon. 2015; 63(6):472-8
 - 145. Silva Junior JM, Malbouisson LM, Nuevo HL, Barbosa LG, Marubayashi LY, Teixeira IC et al. Applicability of the simplified acute physiology score (SAPS 3) in Brazilian hospitals. Revista Brasileira de Anestesiologia. 2010; 60(1):20-31
 - 146. Simpson G, Parker A, Hopley P, Wilson J, Magee C. Pre-operative psoas major measurement compared to P-POSSUM as a prognostic indicator in over-80s undergoing emergency laparotomy. European Journal of Trauma and Emergency Surgery. 2018; Epublication
 - 147. Singh N, Gimpel D, Parkinson G, Conaglen P, Meikle F, Lin Z et al. Assessment of the EuroSCORE II in a New Zealand tertiary centre. Heart, Lung & Circulation. 2018; Epublication
 - 148. Slim K, Panis Y, Alves A, Kwiatkowski F, Mathieu P, Mantion G et al. Predicting postoperative mortality in patients undergoing colorectal surgery. World Journal of Surgery. 2006; 30(1):100-6
 - 149. Sobotka LA, Husain SG, Krishna SG, Hinton A, Pavurula R, Conwell DL et al. A risk score model of 30-day readmission in ulcerative colitis after colectomy or proctectomy. Clinical and Translational Gastroenterology. 2018; 9(8):175
 - 150. Srilata M, Padhy N, Padmaja D, Gopinath R. Does Parsonnet scoring model predict mortality following adult cardiac surgery in India? Annals of Cardiac Anaesthesia. 2015; 18(2):161-9
 - 151. Strilchuk L, Besh D. Estimation of cardiosurgical intervention risk according to EuroSCORE in patients with acute coronary syndrome and different gallbladder conditions before coronary artery bypass grafting. Kardiochirurgia I Torakochirurgia Polska. 2018; 15(4):238-240
 - 152. Suresh V, Levites H, Peskoe S, Hein R, Avashia Y, Erdmann D. Validation of the American College of Surgeons national surgical quality improvement program risk model for patients undergoing panniculectomy. Annals of Plastic Surgery. 2019; 83(1):94-98
- 44 153. Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T et al.
 45 Comparison of preoperative inflammation-based prognostic scores in patients with
 46 colorectal cancer. Annals of Surgery. 2018; 267(3):527-531

- 1 154. Tambyraja AL, Murie JA, Chalmers RT. Prediction of outcome after abdominal aortic aneurysm rupture. Journal of Vascular Surgery. 2008; 47(1):222-30
 - 155. Teeuwen PH, Bremers AJ, Groenewoud JM, van Laarhoven CJ, Bleichrodt RP. Predictive value of POSSUM and ACPGBI scoring in mortality and morbidity of colorectal resection: a case-control study. Journal of Gastrointestinal Surgery. 2011; 15(2):294-303
 - 156. Teoh D, Halloway RN, Heim J, Vogel RI, Rivard C. Evaluation of the American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator in gynecologic oncology patients undergoing minimally invasive surgery. Journal of Minimally Invasive Gynecology. 2017; 24(1):48-54
 - 157. ter Horst R, Markou AL, Noyez L. Prognostic value of preoperative quality of life on mortality after isolated elective myocardial revascularization. Interactive Cardiovascular and Thoracic Surgery. 2012; 15(4):651-4
 - 158. Thiels CA, Yu D, Abdelrahman AM, Habermann EB, Hallbeck S, Pasupathy KS et al. The use of patient factors to improve the prediction of operative duration using laparoscopic cholecystectomy. Surgical Endoscopy. 2017; 31(1):333-340
 - 159. Tian R, Xu H, Lv S. The use of a modified EuroSCORE to evaluate mortality risk in percutaneous coronary intervention. Annals of Thoracic and Cardiovascular Surgery. 2014; 20(1):32-7
 - 160. Tominaga T, Takeshita H, Takagi K, Kunizaki M, To K, Abo T et al. E-PASS score as a useful predictor of postoperative complications and mortality after colorectal surgery in elderly patients. International Journal of Colorectal Disease. 2016; 31(2):217-25
 - 161. Tran Ba Loc P, du Montcel ST, Duron JJ, Levard H, Suc B, Descottes B et al. Elderly POSSUM, a dedicated score for prediction of mortality and morbidity after major colorectal surgery in older patients. British Journal of Surgery. 2010; 97(3):396-403
 - 162. Traven SA, Reeves RA, Sekar MG, Slone HS, Walton ZJ. New 5-factor modified frailty index predicts morbidity and mortality in primary hip and knee arthroplasty. Journal of Arthroplasty. 2019; 34(1):140-144
 - 163. Tsaousi GG, Pitsis AA, Ioannidis GD, Pourzitaki CK, Yannacou-Peftoulidou MN, Vasilakos DG. Implementation of EuroSCORE II as an adjunct to APACHE II model and SOFA score, for refining the prognostic accuracy in cardiac surgical patients. Journal of Cardiovascular Surgery. 2015; 56(6):919-27
 - 164. Tyritzis SI, Papadoukakis S, Katafigiotis I, Adamakis I, Anastasiou I, Stravodimos KG et al. Implementation and external validation of Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) score for predicting complications in 74 consecutive partial nephrectomies. BJU International. 2012; 109(12):1813-8
 - 165. Vaid S, Bell T, Grim R, Ahuja V. Predicting risk of death in general surgery patients on the basis of preoperative variables using American College of Surgeons National Surgical Quality Improvement Program data. Permanente Journal. 2012; 16(4):10-7
 - 166. Varela Barca L, Lopez-Menendez J, Navas Elorza E, Moya Mur JL, Centella Hernendez T, Redondo Palacios A et al. Long-term prognosis after surgery for infective endocarditis: Distinction between predictors of early and late survival. Enfermedades Infecciosas y Microbiología Clínica. 2019; 37(7):435-440
 - Vather R, Zargar-Shoshtari K, Adegbola S, Hill AG. Comparison of the possum, P-POSSUM and Cr-POSSUM scoring systems as predictors of postoperative mortality in patients undergoing major colorectal surgery. ANZ Journal of Surgery. 2006; 76(9):812-6

- 1 168. Veeravagu A, Li A, Swinney C, Tian L, Moraff A, Azad TD et al. Predicting complication risk in spine surgery: a prospective analysis of a novel risk assessment tool. Journal of Neurosurgery Spine. 2017; 27(1):81-91
 - 169. Wang H, Wang H, Chen T, Liang X, Song Y, Wang J. Evaluation of the POSSUM, P-POSSUM and E-PASS scores in the surgical treatment of hilar cholangiocarcinoma. World Journal of Surgical Oncology. 2014; 12:191
 - 170. Wang TK, Choi DH, Stewart R, Gamble G, Haydock D, Ruygrok P. Comparison of four contemporary risk models at predicting mortality after aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery. 2015; 149(2):443-8
 - 171. Wang TK, Oh T, Voss J, Gamble G, Kang N, Pemberton J. Comparison of contemporary risk scores for predicting outcomes after surgery for active infective endocarditis. Heart and Vessels. 2015; 30(2):227-34
 - 172. Wang X, Hu Y, Zhao B, Su Y. Predictive validity of the ACS-NSQIP surgical risk calculator in geriatric patients undergoing lumbar surgery. Medicine. 2017; 96(43):e8416
 - 173. Wani NA, Parray FQ, Safdar G. "POSSUM": a good indicator of morbidity and mortality in calcular disease of biliary tract. JK Practitioner. 2005; 12(1):6-10
 - 174. Wendt D, Thielmann M, Kahlert P, Kastner S, Price V, Al-Rashid F et al. Comparison between different risk scoring algorithms on isolated conventional or transcatheter aortic valve replacement. Annals of Thoracic Surgery. 2014; 97(3):796-802
 - 175. Wingert NC, Gotoff J, Parrilla E, Gotoff R, Hou L, Ghanem E. The ACS NSQIP risk calculator is a fair predictor of acute periprosthetic joint infection. Clinical Orthopaedics and Related Research. 2016; 474(7):1643-8
 - 176. Wolters U, Mannheim S, Wassmer G, Brunkwall J. What is the value of available risk-scores in predicting postoperative complications after aorto-iliac surgery? A prospective non randomized study. Journal of Cardiovascular Surgery. 2006; 47(2):177-85
 - 177. Yap MKC, Ang KF, Gonzales-Porciuncula LA, Esposo E. Validation of the American College of Surgeons risk calculator for preoperative risk stratification. Heart Asia. 2018; 10(2):e010993
 - 178. Ye IB, Girdler SJ, Cheung ZB, White SJ, Ranson WA, Cho SK. Risk factors associated with 30-day mortality after open reduction and internal fixation of vertebral fractures. World Neurosurgery. 2019; 125:e1069-e1073
 - 179. Zattoni D, Montroni I, Saur NM, Garutti A, Bacchi Reggiani ML, Galetti C et al. A simple screening tool to predict outcomes in older adults undergoing emergency general surgery. Journal of the American Geriatrics Society. 2019; 67(2):309-316
 - 180. Zhang B, Sun H, Hu S, Xu J, Wang W, Song Y et al. Predictive value of different scoring systems for early postoperative mortality in patients with a second coronary artery bypass grafting. Chinese Medical Journal. 2014; 127(4):614-7
 - 181. Zheng Z, Fan H, Gao H, Li X, Yuan X, Meng J et al. Mortality risk model for heart valve surgery in China. Journal of Heart Valve Disease. 2013; 22(1):93-101
- 42 182. Zugel NP, Kox M, Lichtwark-Aschoff M, Gippner-Steppert C, Jochum M. Predictive 43 relevance of clinical scores and inflammatory parameters in secondary peritonitis. 44 Bulletin de la Société des Sciences Médicales du Grand-Duché de Luxembourg. 45 2011; (1):41-71

Appendices

1

2

3

Appendix A: Review protocols

Table 4: Review protocol: Preoperative risk stratification tools

| ID | Field | Content |
|-----|---|---|
| 0. | PROSPERO registration number | Not registered |
| 1. | Review title | Which validated preoperative risk stratification tools best identify increased risk of mortality and morbidity in adults who will be undergoing surgery? |
| 2. | Review question | Which validated preoperative risk stratification tools best identify increased risk of mortality and morbidity in adults who will be undergoing surgery? |
| 3. | Objective | To determine which validated preoperative risk stratification tools best identify increased risk of mortality and morbidity in adults who will be undergoing surgery. |
| 4. | Searches | Medline, Embase, The Cochrane Library |
| 5. | Condition or domain being studied | Perioperative care |
| 6. | Population | Inclusion: Adults 18 years and over undergoing surgery. Exclusion: • children and young people aged 17 years and younger • surgery for burns, traumatic brain injury or neurosurgery |
| 7. | Test | Validated risk stratification tools: P-POSSUM score (Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity) SORT (Surgical Outcome Risk Tool) NSQIP (National Surgical Quality Improvement Program) universal surgical risk calculator |
| 8. | Comparator/Reference standard/Confounding factors | n/a |
| 9. | Types of study to be included | Prospective and retrospective cohort studies |
| 10. | Other exclusion criteria | derivation studies internal validation studies non-English language studies studies published before 2000 |
| 11. | Context | n/a |
| | | |

| 12. | Primary outcomes (critical | Mortality | |
|-----|---|---|---|
| | outcomes) | Morbidity | |
| 13. | Secondary outcomes (important outcomes) | n/a | |
| 14. | Data extraction (selection and coding) | EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above. | |
| | | from studie | lised form will be used to extract data es (see <u>Developing NICE guidelines:</u> <u>I section 6.4).</u> |
| | | | neta-analyses performed using Review Manager (RevMan5). |
| 15. | Risk of bias (quality) assessment | Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual | |
| | | 10% of all evidence reviews are quality assured by a senior research fellow. This includes checking: | |
| | | papers were included /excluded appropriately | |
| | | a sample of the data extractions | |
| | | correct methods are used to synthesise data | |
| | | a sample of the risk of bias assessments | |
| | | Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary. | |
| 16. | Strategy for data synthesis | GRADEpro used to assess the quality of evidence for each outcome. | |
| 17. | Analysis of sub-groups | Subgroups | |
| 18. | Type and method of review | • older a | dults (over 60) |
| | 7) | | Intervention |
| | | | Diagnostic |
| | | | Prognostic |
| | | | Qualitative |
| | | | Epidemiologic |
| | | | Service Delivery |
| | | \boxtimes | Risk prediction |

| 19. | Language | English | | |
|-----|--|--|------------|--------------|
| 20. | Country | England | | |
| 21. | Anticipated or actual start date | [x] | | |
| 22. | Anticipated completion date | [x] | | |
| 23. | Stage of review at time of this submission | Review stage | Started | Completed |
| | Submission | Preliminary searches | | V |
| | | Piloting of the study selection process | | > |
| | | Formal screening of search results against eligibility criteria | | V |
| | | Data extraction | | V |
| | | Risk of bias (quality) assessment | | Y |
| | | Data analysis | | V |
| 24. | Named contact | 5a. Named contact National Guideline Centre 5b Named contact e-mail POC@nice.org.uk | | |
| | | | | |
| | | 5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre | | |
| 25. | Review team members | From the National Guideline Centre: | | |
| | | Ms Kate Ashmore | | |
| | | Ms Kate Kelley | | |
| | | Ms Sharon Swaine | | |
| | | Mr Ben Mayer | | |
| | | Ms Maria Smyth | | |
| | | Mr Vimal Bedia Mr Audrius Stonkus | | |
| | | Ms Madelaine Zucker | | |
| | | Ms Margaret Constanti | | |
| | | Ms Annabelle Davis | | |
| | | Ms Lina Gulhane | | |
| 26. | Funding sources/sponsor | This systematic revie | w is being | completed by |

| | | the Natior | nal Guideline Centre which receives |
|-----|--|---|---|
| | | funding fr | om NICE. |
| 27. | Conflicts of interest | All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline. | |
| 28. | Collaborators | Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <u>Developing NICE guidelines: the manual</u> . Members of the guideline committee are available on the NICE website: [NICE guideline webpage]. | |
| 29. | Other registration details | [n/a] | |
| 30. | Reference/URL for published protocol | [Give the citation and link for the published protocol, if there is one.] | |
| 31. | Dissemination plans | NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: | |
| | | notifying registered stakeholders of publication | |
| | | | ing the guideline through NICE's ter and alerts |
| | | issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE. | |
| 32. | Keywords | Perioperative care, surgery, risk prediction | |
| 33. | Details of existing review of same topic by same authors | [n/a] | |
| 34. | Current review status | | Ongoing |
| | | \boxtimes | Completed but not published |
| | | | Completed and published |
| | | | Completed, published and being updated |

| | | | Discontinued |
|-----|------------------------------|-----------------|--------------|
| 35. | Additional information | [n/a] | |
| 36. | Details of final publication | www.nice.org.uk | |

| Table 5: He | alth economic review protocol |
|--------------------|---|
| Review question | All questions – health economic evidence |
| Objectives | To identify health economic studies relevant to any of the review questions. |
| Search criteria | Populations, interventions and comparators must be as specified in the clinical review protocol above. |
| | Studies must be of a relevant health economic study design (cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis, cost-consequences analysis, comparative cost analysis). |
| | Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) |
| | Unpublished reports will not be considered unless submitted as part of a call for evidence. |
| | Studies must be in English. |
| Search strategy | A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below. |
| Review strategy | Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded. |
| | Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014). 108 |
| | Inclusion and exclusion criteria |
| | • If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. |
| | If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. |
| | • If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included. |
| | Where there is discretion |
| | The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below. |

The health economist will be guided by the following hierarchies. Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost-utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

The more closely the clinical effectiveness data used in the health economic
analysis match with the outcomes of the studies included in the clinical review the
more useful the analysis will be for decision-making in the guideline. For example,
economic evaluations based on observational studies will be excluded, when the
clinical review is only looking for RCTs,

Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018. 108

For more detailed information, please see the Methodology Review.

B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Table 6: Database date parameters and filters used

| , | | | | |
|------------------------------|---|--------------------|--|--|
| Database | Dates searched | Search filter used | | |
| Medline (OVID) | 1946 – 30 May 2019 | Exclusions | | |
| Embase (OVID) | 1974 – 30 May 2019 | Exclusions | | |
| The Cochrane Library (Wiley) | Cochrane Reviews to 2019 Issue 5 of 12 CENTRAL to 2019 Issue 5 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4 | None | | |

12 Medline (Ovid) search terms

| 1. | exp Preoperative Care/ or Preoperative Period/ |
|-----|--|
| 2. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab. |
| 3. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 4. | or/1-3 |
| 5. | limit 4 to English language |
| 6. | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) |
| 7. | 5 not 6 |
| 8. | letter/ |
| 9. | editorial/ |
| 10. | news/ |
| 11. | exp historical article/ |
| 12. | Anecdotes as Topic/ |
| 13. | comment/ |
| 14. | case report/ |
| 15. | (letter or comment*).ti. |
| 16. | or/8-15 |
| 17. | randomized controlled trial/ or random*.ti,ab. |
| 18. | 16 not 17 |

1

2

3

4

5

6

7

8

10

| 19. exp Preoperative Care/ or Preoperative Penod/ (pre-operat" or preoperat" or pre-surg" or presurg"),ti,ab. ((before or prior or advance or pre or prepar") adj3 (surg" or operat" or anaesthes" or anaesthes"),ti,ab. 22. or/1-3 23. limit 4 to English language (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*),ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice),ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score"),ti,ab. 50. ((risk" or predict" or prognos") adj2 (tool" or rule" or index" or indices or score" or scoring or scale" or model" or system" or algorithm" or stratif" or criteria or calculat")),ti,ab. 50. ((risk" or predict" or prognos") adj2 (tool" or rule" or index" or indices or scoree" or scoring or scale" or model" or system" or algorithm" or stratif" or criteria or calculat")),ti,ab. 50. (727-32 52. 26 and 33 | 10 | over Propherative Care/ or Propherative Pariet/ |
|--|-----|---|
| 21. ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*).it,ab. 22. or/1-3 3. limit 4 to English language 24. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animals, Laboratory/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*).ti,ab. | 19. | exp Preoperative Care/ or Preoperative Period/ |
| anesthes*)).ti,ab. 22. or/1-3 23. limit 4 to English language 24. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. *SURT.ti,ab. *SURT | _ | |
| 23. limit 4 to English language 24. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 Decision Support Techniques/ 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 21. | |
| 24. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 22. | or/1-3 |
| middle age/ or exp aged/) 25. 5 not 6 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 23. | limit 4 to English language |
| 26. letter/ 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 82. exp Animals, Laboratory/ 43. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 24. | |
| 27. editorial/ 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 25. | 5 not 6 |
| 28. news/ 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 26. | letter/ |
| 29. exp historical article/ 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 27. | editorial/ |
| 30. Anecdotes as Topic/ 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 28. | news/ |
| 31. comment/ 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 29. | exp historical article/ |
| 32. case report/ 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 30. | Anecdotes as Topic/ |
| 33. (letter or comment*).ti. 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 31. | comment/ |
| 34. or/8-15 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 32. | case report/ |
| 35. randomized controlled trial/ or random*.ti,ab. 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. | 33. | (letter or comment*).ti. |
| 36. 16 not 17 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 34. | or/8-15 |
| 37. animals/ not humans/ 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 35. | randomized controlled trial/ or random*.ti,ab. |
| 38. exp Animals, Laboratory/ 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 36. | 16 not 17 |
| 39. exp Animal Experimentation/ 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 37. | animals/ not humans/ |
| 40. exp Models, Animal/ 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 38. | exp Animals, Laboratory/ |
| 41. exp Rodentia/ 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 39. | exp Animal Experimentation/ |
| 42. (rat or rats or mouse or mice).ti. 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 40. | exp Models, Animal/ |
| 43. or/18-24 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 41. | exp Rodentia/ |
| 44. 7 not 25 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 42. | (rat or rats or mouse or mice).ti. |
| 45. Decision Support Techniques/ 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 43. | or/18-24 |
| 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 44. | 7 not 25 |
| 46. Health Status Indicators/ 47. (POSSUM or "Physiological and Operative Severity Score").ti,ab. 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 45. | Decision Support Techniques/ |
| 48. SORT.ti,ab. 49. "Surgical Outcome Risk Tool".ti,ab. 50. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 46. | |
| "Surgical Outcome Risk Tool".ti,ab. ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. or/27-32 | 47. | (POSSUM or "Physiological and Operative Severity Score").ti,ab. |
| ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. or/27-32 | 48. | SORT.ti,ab. |
| scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. 51. or/27-32 | 49. | "Surgical Outcome Risk Tool".ti,ab. |
| | 50. | scoring or scale* or model* or system* or algorithm* or stratif* or criteria or |
| 52. 26 and 33 | 51. | or/27-32 |
| | 52. | 26 and 33 |

Embase (Ovid) search terms

| 1. | *preoperative care/ or *preoperative period/ |
|----|--|
| 2. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab. |
| 3. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 4. | or/1-3 |
| 5. | limit 4 to English language |
| 6. | (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp |

| | middle age/ or exp aged/) |
|-----|--|
| 7. | 5 not 6 |
| 8. | letter.pt. or letter/ |
| 9. | note.pt. |
| 10. | editorial.pt. |
| 11. | case report/ or case study/ |
| 12. | (letter or comment*).ti. |
| 13. | or/8-12 |
| 14. | randomized controlled trial/ or random*.ti,ab. |
| 15. | 13 not 14 |
| 16. | animal/ not human/ |
| 17. | nonhuman/ |
| 18. | exp Animal Experiment/ |
| 19. | exp Experimental Animal/ |
| 20. | animal model/ |
| 21. | exp Rodent/ |
| 22. | (rat or rats or mouse or mice).ti. |
| 23. | or/15-22 |
| 24. | 7 not 23 |
| 25. | Health Status Indicator/ |
| 26. | (POSSUM or "Physiological and Operative Severity Score").ti,ab. |
| 27. | SORT.ti,ab. |
| 28. | "Surgical Outcome Risk Tool".ti,ab. |
| 29. | ((risk* or predict* or prognos*) adj2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)).ti,ab. |
| 30. | or/25-29 |
| 31. | 24 and 30 |

Cochrane Library (Wiley) search terms

| #1. | MeSH descriptor: [Preoperative Care] this term only |
|------|---|
| #2. | MeSH descriptor: [Preoperative Period] this term only |
| #3. | MeSH descriptor: [Perioperative Nursing] this term only |
| #4. | (pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*):ti,ab |
| #5. | (before or prior or advance) near/3 (surg* or operat* or anaesthes* or anesthes*):ti,ab |
| #6. | (or #1-#5) |
| #7. | MeSH descriptor: [Decision Support Techniques] this term only |
| #8. | MeSH descriptor: [Health Status Indicators] this term only |
| #9. | (POSSUM or "Physiological and Operative Severity Score"):ti,ab |
| #10. | SORT:ti,ab |
| #11. | "Surgical Outcome Risk Tool":ti,ab |
| #12. | ((risk* or predict* or prognos*) near/2 (tool* or rule* or index* or indices or score* or scoring or scale* or model* or system* or algorithm* or stratif* or criteria or calculat*)):ti,ab |
| #13. | (or #7-#12) |
| #14. | #6 and #13 |
| | calculat*)):ti,ab (or #7-#12) |

1 B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to the perioperative care population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional health economics searches were run on Medline and Embase.

Table 7: Database date parameters and filters used

| Database | Dates searched | Search filter used |
|---|--|-------------------------------------|
| Medline | 2014 – 30 May 2019 | Exclusions Health economics studies |
| Embase | 2014 – 30 May 2019 | Exclusions Health economics studies |
| Centre for Research and Dissemination (CRD) | HTA - Inception - 02 May 2019 NHSEED - Inception to 02 May 2019 | None |

9 Medline (Ovid) search terms

2

3

4

6

7

| 1. | exp Preoperative Care/ or exp Perioperative Care/ or exp Perioperative Period/ or exp Perioperative Nursing/ |
|-----|--|
| 2. | ((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab. |
| 3. | ((perioperative* or peri-operative* or intraoperative* or intra-operative* or intra-surg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab. |
| 4. | ((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab. |
| 5. | ((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 6. | 1 or 2 or 3 or 4 or 5 |
| 7. | (intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or peroperat* or peri-operat*).ti,ab. |
| 8. | ((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 9. | 7 or 8 |
| 10. | postoperative care/ or exp Postoperative Period/ or exp Perioperative nursing/ |
| 11. | (postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab. |
| 12. | (after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 13. | (post adj3 (operat* or anaesthes* or anesthes*)).ti,ab. |
| 14. | 10 or 11 or 12 or 13 |
| 15. | exp Preoperative Care/ or Preoperative Period/ |
| 16. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab. |
| 17. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 18. | 15 or 16 or 17 |
| 19. | 6 or 9 or 14 or 18 |
| 20. | letter/ |
| 21. | editorial/ |

| 22. news/ 23. exp historical article/ 24. Anecdotes as Topic/ 25. comment/ 26. case report/ 27. (letter or comment*).ti. 28. ot/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animal Experimentation/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 59. 41 and 58 | 22 | nowe/ |
|---|-----|--|
| 24. Anecdotes as Topic/ 25. comment/ 26. case report/ 27. (letter or comment*).ti. 28. or/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animals, Laboratory/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, pharmaceutical/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 66. (financ* or fee or fees).ti,ab. 67. (value adj2 (money or monetary)).ti,ab. | | |
| 25. comment/ 26. case report/ 27. (letter or comment*).ti. 28. or/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animal Experimentation/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (value adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 66. (financ* or fee or fees).ti,ab. 67. (value adj2 (money or monetary)).ti,ab. | | |
| 26. case report/ 27. (letter or comment*).ti. 28. or/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animals Laboratory/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, nursing/ 47. Economics, nursing/ 48. economics, nursing/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | | · |
| 27. (letter or comment*).ti. 28. or/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animals Laboratory/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, nursing/ 48. economics, nursing/ 48. economics, nursing/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | | |
| 28. of/20-27 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animals, Laboratory/ 33. exp Animals, Laboratory/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | | |
| 29. randomized controlled trial/ or random*.ti,ab. 30. 28 not 29 31. animals/ not humans/ 32. exp Animals, Laboratory/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, nursing/ 48. economics, parmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | | |
| 30. 28 not 29 31. animals/ not humans/ 32. exp Animals, Laboratory/ 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | | |
| animals/ not humans/ a. exp Animals, Laboratory/ 3. exp Models, Animal/ 3. exp Rodentia/ 4. exp exp limit 38 to English language 4. (exc child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, Hospital/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 29. | randomized controlled trial/ or random*.ti,ab. |
| as. exp Animals, Laboratory/ as. exp Models, Animal/ exp Models, Animal/ as. exp Rodentia/ (rat or rats or mouse or mice).ti. as. 19 not 37 as. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. as not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 30. | 28 not 29 |
| 33. exp Animal Experimentation/ 34. exp Models, Animal/ 35. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, nursing/ 48. economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 31. | animals/ not humans/ |
| as. exp Models, Animal/ sexp Rodentia/ (rat or rats or mouse or mice).ti. rot/30-36 limit 38 to English language exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) seconomics/ value of life/ exp "costs and cost analysis"/ exp Economics, Hospital/ exp Economics, nursing/ economics, pharmaceutical/ exp "Fees and Charges"/ budget*.ti,ab. cost*.ti. (cost*.ati, (price* or pricing*).ti,ab. (financ* or fee or fees).ti,ab. (value adj2 (money or monetary)).ti,ab. (value adj2 (money or monetary)).ti,ab. | 32. | exp Animals, Laboratory/ |
| as. exp Rodentia/ 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 33. | exp Animal Experimentation/ |
| 36. (rat or rats or mouse or mice).ti. 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 34. | exp Models, Animal/ |
| 37. or/30-36 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 35. | exp Rodentia/ |
| 38. 19 not 37 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 36. | (rat or rats or mouse or mice).ti. |
| 39. limit 38 to English language 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 37. | or/30-36 |
| 40. (exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, nursing/ 48. economics, nursing/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. | 38. | 19 not 37 |
| middle age/ or exp aged/) 41. 39 not 40 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 39. | limit 38 to English language |
| 42. economics/ 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 40. | |
| 43. value of life/ 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 41. | 39 not 40 |
| 44. exp "costs and cost analysis"/ 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 42. | economics/ |
| 45. exp Economics, Hospital/ 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 43. | value of life/ |
| 46. exp Economics, medical/ 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 44. | exp "costs and cost analysis"/ |
| 47. Economics, nursing/ 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 45. | exp Economics, Hospital/ |
| 48. economics, pharmaceutical/ 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 46. | exp Economics, medical/ |
| 49. exp "Fees and Charges"/ 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 47. | Economics, nursing/ |
| 50. exp budgets/ 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 48. | economics, pharmaceutical/ |
| 51. budget*.ti,ab. 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 49. | exp "Fees and Charges"/ |
| 52. cost*.ti. 53. (economic* or pharmaco?economic*).ti. 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 50. | exp budgets/ |
| (economic* or pharmaco?economic*).ti. (price* or pricing*).ti,ab. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. (financ* or fee or fees).ti,ab. (value adj2 (money or monetary)).ti,ab. or/42-57 | 51. | budget*.ti,ab. |
| 54. (price* or pricing*).ti,ab. 55. (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 52. | cost*.ti. |
| (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. (financ* or fee or fees).ti,ab. (value adj2 (money or monetary)).ti,ab. or/42-57 | 53. | (economic* or pharmaco?economic*).ti. |
| 56. (financ* or fee or fees).ti,ab. 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 54. | (price* or pricing*).ti,ab. |
| 57. (value adj2 (money or monetary)).ti,ab. 58. or/42-57 | 55. | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 58. or/42-57 | 56. | (financ* or fee or fees).ti,ab. |
| 58. or/42-57 | 57. | (value adj2 (money or monetary)).ti,ab. |
| 59. 41 and 58 | 58. | or/42-57 |
| | 59. | 41 and 58 |

Embase (Ovid) search terms

| 1. | *preoperative period/ or *intraoperative period/ or *postoperative period/ or *perioperative nursing/ or *surgical patient/ |
|----|--|
| 2. | ((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine)).ti,ab. |
| 3. | ((perioperative* or peri-operative* or intraoperative* or intra-operative* or intrasurg* or intra-surg* or perioperat* or perioperat*) adj3 (care* or caring or treat* or nurs* or |

| | monitor* or recover* or medicine)).ti,ab. |
|-----|---|
| 4. | ((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 5. | 1 or 2 or 3 or 4 |
| 6. | peroperative care/ or exp peroperative care/ or exp perioperative nursing/ |
| 7. | (intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or peroperat* or perioperat*).ti,ab. |
| 8. | ((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 9. | 6 or 7 or 8 |
| 10. | postoperative care/ or exp postoperative period/ or perioperative nursing/ |
| 11. | (postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*).ti,ab. |
| 12. | (after adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 13. | (post adj3 (operat* or anaesthes* or anesthes*)).ti,ab. |
| 14. | 10 or 11 or 12 or 13 |
| 15. | exp preoperative care/ or preoperative period/ |
| 16. | (pre-operat* or preoperat* or pre-surg* or presurg*).ti,ab. |
| 17. | ((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*)).ti,ab. |
| 18. | 15 or 16 or 17 |
| 19. | 5 or 9 or 14 or 18 |
| 20. | letter.pt. or letter/ |
| 21. | note.pt. |
| 22. | editorial.pt. |
| 23. | case report/ or case study/ |
| 24. | (letter or comment*).ti. |
| 25. | or/20-24 |
| 26. | randomized controlled trial/ or random*.ti,ab. |
| 27. | 25 not 26 |
| 28. | animal/ not human/ |
| 29. | nonhuman/ |
| 30. | exp Animal Experiment/ |
| 31. | exp Experimental Animal/ |
| 32. | animal model/ |
| 33. | exp Rodent/ |
| 34. | (rat or rats or mouse or mice).ti. |
| 35. | or/27-34 |
| 36. | 19 not 35 |
| 37. | limit 36 to English language |
| 38. | (exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/) |
| 39. | 37 not 38 |
| 40. | health economics/ |
| 41. | exp economic evaluation/ |

| 42. | exp health care cost/ |
|-----|--|
| 43. | exp fee/ |
| 44. | budget/ |
| 45. | funding/ |
| 46. | budget*.ti,ab. |
| 47. | cost*.ti. |
| 48. | (economic* or pharmaco?economic*).ti. |
| 49. | (price* or pricing*).ti,ab. |
| 50. | (cost* adj2 (effectiv* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 51. | (financ* or fee or fees).ti,ab. |
| 52. | (value adj2 (money or monetary)).ti,ab. |
| 53. | or/40-52 |
| 54. | 39 and 53 |

NHS EED and HTA (CRD) search terms


| 11110 | and TITA (OND) search terms |
|-------|---|
| #1. | MeSH DESCRIPTOR Preoperative Care EXPLODE ALL TREES |
| #2. | MeSH DESCRIPTOR Perioperative Care EXPLODE ALL TREES |
| #3. | MeSH DESCRIPTOR Perioperative Period EXPLODE ALL TREES |
| #4. | MeSH DESCRIPTOR Perioperative Nursing EXPLODE ALL TREES |
| #5. | (((perioperative* or peri-operative* or intraoperative* or intra-operative* or intra-surg* or intra-surg* or peroperat* or per-operat*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine))) |
| #6. | (((care* or caring or treat* or nurs* or recover* or monitor*) adj3 (before or prior or advance or during or after) adj3 (surg* or operat* or anaesthes* or anesthes*))) |
| #7. | (((pre-operative* or preoperative* or preop* or pre-op* or pre-surg* or presurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine))) |
| #8. | (((postoperative* or postop* or post-op* or post-surg* or postsurg*) adj3 (care* or caring or treat* or nurs* or monitor* or recover* or medicine))) |
| #9. | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 |
| #10. | (* IN HTA) |
| #11. | (* IN NHSEED) |
| #12. | #9 AND #10 |
| #13. | #9 AND #11 |
| #14. | MeSH DESCRIPTOR Intraoperative Care EXPLODE ALL TREES |
| #15. | #1 OR #2 OR #3 OR #4 OR #14 |
| #16. | ((intraoperative* or intra-operative* or intrasurg* or intra-surg* or peroperat* or peroperat* or peri-operat*)) |
| #17. | (((during or duration) adj3 (surg* or operat* or anaesthes* or anesthes*))) |
| #18. | ((postop* or post-op* or post-surg* or postsurg* or perioperat* or peri-operat*)) |
| #19. | ((after adj3 (surg* or operat* or anaesthes* or anesthes*))) |
| #20. | ((post adj3 (operat* or anaesthes* or anesthes*))) |
| #21. | ((pre-operat* or preoperat* or pre-surg* or presurg*)) |
| #22. | (((before or prior or advance or pre or prepar*) adj3 (surg* or operat* or anaesthes* or anesthes*))) |
| #23. | #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 |
| #24. | #10 AND #23 |

Perioperative care: DRAFT FOR CONSULTATION Preoperative risk stratification tools

| #25. | #11 AND #23 |
|------|--------------------------|
| #26. | #12 OR #13 OR #24 OR #25 |

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of risk tools



Appendix D: Clinical evidence tables

| Reference | Baker 2018 ¹¹ |
|--------------------|--|
| Study type | Prospective Cohort study |
| Study sample | Patients were prospectively enrolled from March 2014-2015 and eligible if they were undergoing an abdominal operation |
| Inclusion criteria | 298 patients deemed eligible by their surgical oncologist as an appropriate surgical candidate, and the operation was planned under GA with entry into the Peritoneum. |
| Exclusion criteria | Patients excluded if they underwent an emergent operation |
| Risk tools | ACS NSQIP |
| Outcome | 90 day morbidity |
| Results | ACS NSQIP any complication – OR = 1.042 (CI 1.030-1.116), P value = <0.0001, c-statistic = 0.6061 |

| Reference | Bennett-Guerrero 2003 ¹⁴ |
|--------------------|--|
| Study type | Prospective Cohort study of risk prediction tool |
| Study sample | 2 cohorts of patients undergoing major, non-cardiac surgery over the same time interval (August 1996 to June 1998). One cohort included patients undergoing surgery at the Mount Sinai Hospital, New York and the second cohort included patients undergoing surgery at the Queen Alexandra hospital and St Mary's hospital in Portsmouth. |
| Inclusion criteria | Patients undergoing major, non-cardiac surgery. USA (n=1056). UK (n=1539). |
| Exclusion criteria | None provided |
| Risk tools | P-POSSUM |
| Outcome | Mortality – in hospital mortality |
| Results | UK cohort - predicted mortality rate = 10.2%, observed mortality rate = 9.9 US cohort - predicted mortality rate = 7.8%, observed mortality rate = 2.1% UK cohort - predicted no. of deaths = 156, Observed number of deaths = 152 US cohort - predicted no. of deaths = 82, observed no. of deaths = 22 |

| Reference | Blair 2018 ¹⁷ |
|--------------------|--|
| Study type | Retrospective review of cohort |
| Study sample | Retrospective review of a single institution, multi-surgeon, database of all patients undergoing PN for renal cell carcinoma from February 1998 to June 2015. |
| Inclusion criteria | 470 Patients undergoing PN for renal cell carcinoma. |
| | 272 males and 198 women with a median age of 57 years |
| Exclusion criteria | Patients were excluded if complete records were not available and if the pathology of the tumor was determined to be anything other than RCC. |
| Risk tools | ACS NSQIP surgical risk calculator |
| Outcome | 30 days overall complications and mortality |
| Results | Comparing predicted vs observed outcomes for all patients, the risk of overall complications were significantly under estimated $(9.16\% \text{ vs } 16.81\%, \text{p}<0.001)$ by the NSQIP. $95\% \text{ CI} = -7.65 (-7.07, -7.33)$. Mortality = $(0.33 \text{ vs } 0.21\%, \text{p}<0.001)$ $95\% \text{ CI} = 0.12 (0.09-0.16)$. |

| Reference | Bodea 2018 ¹⁸ |
|--------------------|--|
| Study type | Retrospective cohort study |
| Study sample | Elective surgery patients at the Surgical Clinic no. 3 Cluj Romania between July 2013- December 2015. |
| Inclusion criteria | 113 Participants undergoing elective Pancreaticoduodenectomy for periampullary malignant tumors. 64 males and 49 females, aged between 22-81 (median of 64). |
| Exclusion criteria | No exclusion criteria provided |
| Risk tools | P-POSSUM |
| Outcome | Mortality Morbidity |
| Results | The c-statistic was 0.61 for morbidity and 0.61 for mortality. Comparing the observed and estimated morbidity and mortality, statistical significant results (p=0.05 and p=0.03, respectively) Morbidity =ROC sensibility 0.65 [Cl95% (0.562, 0.735)] and specificity 0.5 [Cl95% (0.388, 0.606)] |

| Reference | Bonaventura 2019 ²⁰ |
|------------|--------------------------------|
| Study type | Retrospective cohort study |

| 2 |
|---|
| _ |

| Reference | Bonaventura 2019 ²⁰ |
|--------------------|---|
| Study sample | Patients undergoing cholecystectomy for acute cholecystitis at the surgery unit of Ospedale Policlinico San Martino hospital between 2005 and 2013. |
| Inclusion criteria | 271 patients undergoing cholecystectomy for acute chloecystitis |
| Exclusion criteria | Patients who were younger than 18 were excluded |
| Risk tools | CCI ASA |
| Outcome | In hospital complications |
| Results | CCI in hospital complications – c-statistic = 0.662 (p= 0.0086) ASA in hospital complications – OR = 1.92 (CI 1.04-3.54) p=<0.001 |

| Reference | Boyd 2019 ²² |
|--------------------|--|
| Study type | Retrospective cohort study |
| Study sample | Records of patients who underwent pelvic reconstructive and incontinence surgery in a single tertiary centre from July 2014 to July 2017 were reviewed |
| Inclusion criteria | 731 women patients 18 years or older undergoing surgery for pelvic organ prolapse or incontinence by all routes were included |
| Exclusion criteria | Non pelvic reconstructive procedures or procedures with same day hospital discharge were excluded. |
| Risk tools | ACS NSQIP risk calculator |
| Outcome | 30 day Mortality |
| Results | NSQIP mortality – 0 event rate NSQIP any complication - C statistic = 0.547 (p 0.039), BS = 35.037 |
| Comments | Women only and excluded all same day DC patients |

| Reference | Bronheim 2018 ²⁴ |
|--------------------|---|
| Study type | Retrospective review of cohort |
| Study sample | Retrospective review of ACS-NSQIP database from 2006 to 2014 |
| Inclusion criteria | 52,066 adult patients undergoing posterior lumbar decompression surgery |
| Exclusion criteria | None provided |
| Risk tools | ASA score |

| Reference | Bronheim 2018 ²⁴ |
|-----------|--|
| Outcome | 30 days mortality and morbidity |
| Results | c-statistic results as a predictor for any complication = 0.770 SE 0.023 (P= <0.001 CI= 0.726 - 0.815) c-statistic results as a predictor for mortality = 0.800 SE 0.002 (P= <0.001 CI= 0.796 - 0.804) |

| Reference | Bulow 2019 ²⁶ |
|--------------------|---|
| Study type | Retrospective review of cohort |
| Study sample | Retrospective review of patients from the Swedish Hip Arthroplasty register between 2005 and 2012 |
| Inclusion criteria | 43,224 patients treated with hip arthroplasty for a femoral neck fracture |
| Exclusion criteria | None provided |
| Risk tools | CCI |
| Outcome | 30 and 90 days mortality and long term mortality – 1 year post op |
| Results | c-statistic 30 day mortality = 0.59 c-statistic 90 day mortality = 0.59 c-statistic 1 year mortality = 0.58 |

| Reference | Cengiz 2014 ³¹ |
|--------------------|--|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | 335 consecutive patients undergoing colorectal cancer surgery between 2002 and 2012 in third-level healthcare centres. Male patients (n = 196) consisted 58.5% of all patients and 38.2% (n = 128) of all patients were over 70 years of age. Number of elective surgeries or curative resection was 279 (83.3%) or 265 (79.1%), respectively. |
| Inclusion criteria | Consecutive patients undergoing colorectal cancer surgery |
| Exclusion criteria | None provided |
| Risk tools | Possum P-possum ACPGBI scores |
| Outcome | Mortality within postoperative 30-days that extend the duration of hospital stay. |
| Results | Mortality and morbidity were observed in 17 and 109 patients, respectively. Mortality predictive scores: |

| Reference | Cengiz 2014 ³¹ |
|-----------|--|
| | POSSUM: c-statistic = 89.7, 95% CI = 86.0-92.8, sensitivity = 88.2, specificity = 78.6. |
| | P-POSSUM: c-statistic = 90.4, 95% CI = 86.7-93.3, sensitivity = 94.1, specificity = 73.0 |
| | ACPGBI score: c-statistic = 78.1, 95% CI = 73.3-82.4, sensitivity = 76.5, specificity = 70.8 |

| Reference | Chun 2018 ³² |
|--------------------|---|
| Study type | Retrospective case control study |
| Study sample | Patients who had undergone surgery at a single tertiary care centre. |
| Inclusion criteria | 217 patients who had undergone spinal surgery for various spine diseases. |
| | 103 men and 114 women with a mean age of 57.0 years. |
| Exclusion criteria | None included |
| Risk tools | E-PASS |
| | POSSUM |
| Outcome | Postoperative complications within 1 month after surgery |
| Results | The c-statistic for predicted post-operative complications was 0.588 for the E-PASS and 0.721 for the POSSUM. |

| Reference | Cologne 2015 ³⁶ |
|--------------------|--|
| Study type | Retrospective cohort study |
| Study sample | Consecutive laparoscopic colon resections performed on an elective basis from April 2011 through July 2014 by two colorectal surgeons at a tertiary referral centre |
| Inclusion criteria | 116 patients were included if they were older than 18 years, if the procedure was performed by one of the 2 specified surgeons, if a preoperative ACS risk score was calculated and if completed postoperative medical records were available. |
| Exclusion criteria | None provided |
| Risk tools | ACS NSQIP risk calculator |
| Outcome | Mortality Any complication |
| Results | Observed vs predicted risk for any complication = (17.3% vs 19.4%, p=0.05), mortality = (1.07% vs 0.83%, p=0.86). |

| Reference Dahlke 20 | 014 ³⁸ |
|---------------------|-------------------|
|---------------------|-------------------|

| Reference | Dahlke 2014 ³⁸ |
|--------------------|---|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | Data obtained from the ACS NSQIP participant file 2011 release for patients undergoing a broad range of surgeries across all surgical specialities. |
| Inclusion criteria | 238,649 patients were included for analysis if they underwent a general surgery. |
| | 58.8% female with a median age of 54.1 years. |
| Exclusion criteria | None provided |
| Risk tools | ACS NSQIP – All information |
| Outcome | Overall Morbidity |
| Results | AUC/c-stastic for overall morbidity = 0.861 |

| Reference | Dutta 2011 ⁴³ |
|--------------------|--|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | 121 Patients undergoing oesophago-gastric cancer resections in Glasgow Royal Infirmary from January 2005 to May 2009 |
| Inclusion criteria | Patients undergoing oesophago-gastric curative cancer resections who had data to score the POSSUM, P-POSSUM, O-POSSUM, and mGPS models were included in the study |
| Exclusion criteria | None provided |
| Risk tools | Possum |
| | P-possum |
| Outcome | Mortality and Morbidity |
| | Both short term and long term survival were recorded |
| Results | Observed morbidity was 49%, whereas POSSUM predicted post-operative morbidity in 60%, giving an overall standardised morbidity ratio of 0.25 and 0.71. ROC analysis for the POSSUM morbidity equation (c-statistic 0.639, 95% CI 0.541–0.737, P = 0.008) |
| | ROC analysis for the P-POSSUM mortality equation gave c-statistic 0.808 (95% CI $0.55-1.06$, $P = 0.020$), POSSUM (c-statistic 0.759 , 95% CI $0.48-1.04$, $P = 0.051$) |

| Reference | Egberts 2011 ⁴⁶ |
|--------------|---|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | The medical records of 191 patients undergoing surgery for IBD at the Department of General Surgery and Thoracic Surgery at the |

| Reference | Egberts 2011 ⁴⁶ |
|--------------------|---|
| | University Hospital of Kiel from 2004 to 2009 were analysed retrospectively. |
| | There were a total of 191 patients (81 male and 110 female) with a mean age of 38.1 years (range 5–75). There were 158 patients operated on for Crohn's disease and 33 patients for UC |
| Inclusion criteria | Patients with a histologically proven MC or CU and an abdominal surgery were included. |
| Exclusion criteria | Patients who presented with a perianal affection and were treated with proctological techniques (seton drainage, fistula repair, etc.) without abdominal surgery were excluded from this study. |
| Risk tools | Possum |
| Outcome | Mortality Morbidity |
| Results | The overall complication rate was 27.7%, and the mortality was 0.5%. The morbidity rate predicted by POSSUM was 28.4% and the mortality rate 7.2%. |

| Reference | Egberts 2011 ⁴⁵ |
|--------------------|---|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | The medical records of 143 patients with cutaneous melanoma who underwent a radical lymph node dissection (RLND) at the Department of General Surgery and Thoracic Surgery at the University Hospital of Kiel from 1985 to 2008 were analysed retrospectively. There were 143 patients (59 male, 84 female) with a mean age of 58.1 years (range: 20–89 years) |
| Inclusion criteria | Patients with cutaneous melanoma who underwent a radical lymph node dissection (RLND) |
| Exclusion criteria | None provided |
| Risk tools | Possum |
| Outcome | Mortality Morbidity |
| Results | The actual mortality rate was 0% whereas the rate estimated by POSSUM was 8.3%. The POSSUM (ie predicted) morbidity rate for all patients together was 32.9% and the observed morbidity for all patients was similar at 28.0%. |

| Reference | Fu 2019 ⁵² |
|--------------------|--|
| Study type | Retrospective chart review of ACS NSQIP |
| Study sample | Data from the ACS NSQIP from 2005 to 2015 was extracted |
| Inclusion criteria | 10,527 patients who underwent total shoulder arthroplasty were identified in the NSQIP |
| Exclusion criteria | Cases missing age, sex, height, weight and thise younger than 18 years old. |

| Reference | Fu 2019 ⁵² |
|------------|--|
| Risk tools | ASA score Modified Charlston Comorbidity Index |
| Outcome | 30 day postoperative adverse event |
| Results | ASA any adverse event – c-statistic = 0.607 ($0.587 - 0.627$) mCCI any adverse event - c-statistic = 0.555 ($0.536 - 0.575$) |

| Reference | Golan 2018 ⁵⁴ |
|--------------------|--|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | Patients in prospectively maintained database who underwent open RC with either ileal conduit or orthotopic neobladder urinary diversion for bladder cancer between Jan 2007 and Dec 2016. |
| Inclusion criteria | 954 patients undergoing radical cystectomy with uniary diversion Males = 752 and median age =70 (62-76) |
| Exclusion criteria | Patients who underwent a continent catherisable unirary diversion were not included. |
| Risk tools | ACS NSQIP risk calculator |
| Outcome | Mortality and 30 days post-operative any complication |
| Results | Predicted vs observed any complication= 30.7% vs 40.3% and mortality = 1.3% vs 2.2%. Any complication c-statistic = 0.58 (p<0.001), mortality c-statistic = 0.62 (p=0.02). |

| Reference | Hirose 2014 ⁵⁷ |
|--------------------|--|
| Study type | Retrospective cohort analysis of risk prediction tools |
| Study sample | 601 consecutive patients who underwent spinal surgery between January 2005 and December 2009 at Kumamoto University Hospital. |
| Inclusion criteria | Patients who underwent spinal surgery. The surgical procedures included laminoplasty and anterior fusion to treat cervical disorders (169 patients); posterior fusion for thoracic disorders (16 patients); laminectomy, posterior fusion, and discectomy for lumbar disorders (259 patients); resection of spinal tumors (117 patients); spinal fusion for scoliosis (27 patients); and curettage or spinal fusion for pyogenic spondylitis (13 patients). 327 were male and 274 were female, and their mean age was 58.7 years (range 7–88 years). |
| Exclusion criteria | None provided |

| Reference | Hirose 2014 ⁵⁷ |
|------------|--|
| Risk tools | POSSUM |
| | E-PASS |
| Outcome | Mortality and Morbidity |
| Results | The ROC curves of each model for the detection of postoperative complications were evaluated - the c-statistic of predicted morbidity rate (PMR) for E-PASS was 0.668 (95% CI 0.596–0.739) and higher than for POSSUM (0.588; 95% CI 0.513–0.663). |

| Reference | Hirose 2015 ⁵⁸ |
|--------------------|--|
| Study type | A single centre retrospective cohort study |
| Study sample | Retrospective review of 275 consecutive patients who underwent spinal surgery between Jan 2008 and Dec 2009 at Kumamoto University Hospital. |
| Inclusion criteria | 275 patients undergoing spinal surgery. The same 4 surgeons performed the procedures. 146 male and 129 females, mean age was 59.7 years. |
| Exclusion criteria | None provided |
| Risk tools | E-PASS |
| Outcome | Total postoperative morbidities |
| Results | Total postoperative morbidities, c-statistic = 0.681 |

| Reference | Hobson 2007 ⁶⁰ |
|--------------------|---|
| Study type | Prospective comparison study |
| Study sample | All patients undergoing surgery in the emergency theatre of the Leicester general hospital over a 4-month period from June to September 2003. |
| Inclusion criteria | 163 patients undergoing surgery in the emergency theatre including general surgery, gynaecology, renal, urology and vascular. |
| Exclusion criteria | None provided |
| Risk tools | POSSUM P-POSSUM |
| Outcome | 30 day mortality 60 day/in hospital mortality |
| Results | 30 day mortality, c-statistic = POSSUM - 0.946, P-POSSUM - 0.940. |

| Reference | Hobson 2007 ⁶⁰ |
|-----------|--|
| | In hospital Mortality, c-statistic = POSSUM – 0.932, P-POSSUM – 0.928. |

| Reference | Huisman 2014 ⁶⁴ | | |
|--------------------|---|--|--|
| Study type | Prospective cohort study | | |
| Study sample | Recruitment took place in 6 different countries at 11 medical centers between September 2008 and January 2012 and included 263 cancer patients scheduled for elective surgery | | |
| Inclusion criteria | A cohort of cancer patients aged 70 or over who were candidate for elective surgery under general anesthesia, were invited to take part by the local coordinator. The median age of this cohort was 76 years (Range: 70–96) and 66.5% of patients were female. The majority of surgical procedures were laparotomies (n = 156; 59.3%) and breast cancer surgeries (n = 76; 28.9%). | | |
| Exclusion criteria | Patients requiring emergency surgical management (within 24 hours) were excluded from this study. Medical centres that included less than 10 patients were excluded from analysis, which resulted in the analysis of 263 patients | | |
| Risk tools | Timed up and go ASA classification | | |
| Outcome | Mortality and 30 day morbidity | | |
| Results | In a univariable logistic regression analysis the TUG and ASA were not predictive of 30-day mortality. For morbidity - Sensitivity of a high TUG was 42.0% and specificity was 89.8%. The c-statistic was 0.66 (95%-CI = 0.57–0.75; p<0.001). Sensitivity of ASA ≥3 was 57.1% and specificity was 58.5%. The c-statistic was 0.58 (95%-CI = 0.49–0.67, p = 0.09). | | |

| Reference | Igari 2013 ⁶⁵ | | |
|--------------------|---|--|--|
| Study type | Retrospective cohort analysis of risk prediction tools | | |
| Study sample | Patients undergoing general surgical procedures at Ohta Nishinouchi General Hospital between April 2003 and March 2009 | | |
| Inclusion criteria | 593 Patients aged ≥80 years who underwent surgery under general anaesthesia. 287 male and 387 females, mean age 83 years. | | |
| Exclusion criteria | None provided | | |
| Risk tools | POSSUM P-POSSUM | | |
| Outcome | Postoperative morbidity and mortality within 30 days post operatively | | |

| Reference | Igari 2013 ⁶⁵ | |
|-----------|--|--|
| Results | POSSUM - Observed/expected morbidity ratio was 1.44 and mortality ratio was 0.98 | |
| | P-POSSUM – the O/E ratio was 1.0. | |

| Reference | Katlic 2019 ⁷² | | |
|--------------------|---|--|--|
| Study type | Retrospective cohort study | | |
| Study sample | Patients aged ≥75 years who presented to Sinai Hospital of Baltimore for major elective surgery between September 2012 and July 2016 | | |
| Inclusion criteria | 1025 geriatric surgical patients undergoing major elective surgery including cardiac, thoracic, vascular, orthopaedic, surgical oncology, general surgery, urologic and neurologic. | | |
| Exclusion criteria | None provided | | |
| Risk tools | Charleston Comorbidity index ASA Score Fried's 5 point frailty score | | |
| Outcome | Any NSQIP complication | | |
| Results | Fried's 5 point frailty – c-statistic = 0.70 (p=0.680) ASA score – c-statistic = 0.70 (p=0.755) CCI – c-statistic = 0.64 (p=0.008) | | |

| Reference | Kim 2018 ⁷⁸ | | |
|--------------------|--|--|--|
| Study type | Retrospective cohort study | | |
| Study sample | The national inpatient sample from the USA was queried for patients who underwent a total shoulder arthroplasty or reverse total shoulder arthroplasty between 2002 and 2014 | | |
| Inclusion criteria | 90,491 patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty | | |
| Exclusion criteria | None provided | | |
| Risk tools | Charlston comorbidity index | | |
| Outcome | Any inpatient complication and mortality | | |
| Results | CCI mortality – c-statistic = 0.827 (CI 0.774-0.88) CCI any complication – c-statistic = 0.691 (CI 0.680-0.703) | | |

| Reference | Kong 2013 ⁸² | | | |
|--------------------|--|--|--|--|
| Study type | Temporal validation of a prospective observational study and the external validation was a retrospective observational study | | | |
| Study sample | Major colorectal operations performed at Geelong hospital and Western Hospital from 2008-2010 | | | |
| Inclusion criteria | 474 major colorectal operations performed at Geelong hospital (temporal validation) and 389 cases at Western Hospital (external validation) | | | |
| Exclusion criteria | Patients undergoing surgery for reversal of colostomy or ileostomy, diverting stoma formation, transanal endoscopic microsurgery, and laparotomy or laparscopy with washout of peritoneal cavity. | | | |
| Risk tools | POSSUM P-POSSUM ACPGBI | | | |
| Outcome | Mortality | | | |
| Results | Temporal validation (of BH tool) dataset POSSUM: mortality c-statistic = 0.790 p=<0.001 P-POSSUM: mortality c-statistic = 0.801 p=0.88 ACPGBI: mortality c-statistic = 0.721 p= 0.006 External validation (of BH tool) dataset POSSUM: mortality c-statistic = 0.696 p=<0.0001 P-POSSUM: mortality c-statistic = 0.681 p=0.13 ACPGBI: mortality c-statistic = 0.658 p=<0.0001 | | | |

| Reference | Kwok 2011 ⁸⁷ | | |
|--------------------|---|--|--|
| Study type | Retrospective cohort | | |
| Study sample | Data from ACS NSQIP N=1730 | | |
| Inclusion criteria | Very elderly patients aged 80+ undergoing emergency colon surgery | | |
| Exclusion criteria | Not reported | | |
| Risk tools | ASA Surgical risk scale | | |

| Reference | Kwok 2011 ⁸⁷ | | | |
|-----------|---------------------------------|-------------|---------------------------|--|
| Outcome | Mortality | | | |
| Results | Overall mortality was 489 (28%) | | | |
| | | | | |
| | Tool | C-statistic | Goodness of fit (p value) | |
| | ASA | 0.66 | 0.14 | |
| | Surgical risk scale | 0.66 | 0.14 | |

| Reference | Lakomkin 2018 ⁸⁸ | | |
|--------------------|--|--|--|
| Study type | Retrospective chart review of ACS NSQIP | | |
| Study sample | Data from ACA NSQIP from 2008 to 2014 | | |
| Inclusion criteria | 2,170 patients undergoing spinal tumor resection | | |
| Exclusion criteria | None provided | | |
| Risk tools | ASA score Modified Charlston Comorbidity Index | | |
| Outcome | 30 day Mortality | | |
| Results | ASA – mortality – 'not predictive of any adverse event' CCI – mortality OR = 1.24 (CI= 1.12 – 1.36) P value= <0.001, c-statistic = 0.860 | | |

| Reference | Lima 2019 ⁹⁵ |
|--------------------|--|
| Study type | Prospective observational study |
| Study sample | Patients scheduled to undergo elective surgery during a 3 month period at a University hospital |
| Inclusion criteria | 235 patients over 60 years old scheduled to undergo elective procedures under general, regional or combined anaesthesia for general, gynaecological, plastic, vascular, or orthopaedic surgeries at a university hospital were enrolled. |
| Exclusion criteria | Patients who were admitted to ICU immediately after surgery, submitted to emergency or urgent surgery procedures, unable to speak or understand the Portuguese language or incapable of signing the informed consent were excluded. |
| Risk tools | P-POSSUM |
| Outcome | 30 day Mortality |
| Results | P-POSSUM 30 day mortality AUROC = 0.563 |

| Reference | Markovic 2018 ⁹⁹ | | | |
|--------------------|--|---|----------------------|---|
| Study type | Retrospective chart review | | | |
| Study sample | Pilot study included patients who were being prepared for one of the major non-cardiac surgeries under general anaesthesia. N=78 | | | |
| Inclusion criteria | Patients who we | Patients who were being prepared for extensive non-cardiac surgeries under general anaesthesia. | | |
| Exclusion criteria | Not reported | | | |
| Risk tools | ASA NSQIP SORT | | | |
| Outcome | Mortality | | | |
| Results | Mortality | | | |
| | Test | Event rate (%) | C-statistic (95% CI) | |
| | ASA | | 0.669 (0.506-0.832) | |
| | NSQIP | 14 (18%) | 0.813 (0.702-0.924) | |
| | SORT | | 0.797 (0.671-0.924) | _ |
| Comments | Population/surge | ery characteristics unclear | | |

| Reference | Ngulube 2019 ¹¹⁰ |
|--------------------|--|
| Study type | Prospective observational cohort study |
| Study sample | The study included all consecutively admitted patients undergoing a variety of major general surgical operations at Parirenyatwa Group of Hospitals (PGH) and Harare Central Hospital (HCH) over a 9 month period from January to September of 2015. |
| Inclusion criteria | 181 patients (123 males, 58 females) aged 18 years and above undergoing a major general surgical procedure as defined by the British United Provident Association, with timing ranging from elective to emergency were included. Mean age 47 (SD 18.7) |
| Exclusion criteria | Below the age of 18 years, if managed conservatively, if it was a day case or any procedure categorised as minor and any case falling outside the scope of general surgery. Those also excluded were patients with more than 1 missing result or those requiring admission into a critical care unit post operatively but failed because of shortage of beds and those operated on by surgical trainees with less than 2 years experience. |
| Risk tools | POSSUM |

| Reference | Ngulube 2019 ¹¹⁰ |
|-----------|--|
| | P-POSSUM |
| Outcome | Mortality Morbidity |
| Results | c-statistic for POSSUM morbidity = 0.775 (p<0.0001). O:E ratio = 0.88 c-statistic for POSSUM mortality = 0.818 (p=0.818). O:E ratio = 0.74 c-statistic for P-POSSUM mortality = 0.814 (p<0.000) O:E ratio = 1.06 |

| Reference | Reis 2019 ¹²⁸ |
|--------------------|--|
| Study type | Retrospective cohort study |
| Study sample | All patients admitted to surgical ICU after open vascular surgery from January 2006 to July 2013 in a large academic hospital. |
| Inclusion criteria | 833 patients admitted to surgical ICU after open vascular surgery from January 2006 to July 2013 |
| Exclusion criteria | None provided |
| Risk tools | POSSUM |
| Outcome | Hospital mortality |
| Results | POSSUM hospital mortality – observed/expected ration of 0.98 (43/44) and AUROC = (0.829) |

| Reference | Rivard 2016 ¹²⁹ | | | | |
|--------------------|--|--------------------------|-----------------------------|-----------------------------|----------------------------|
| Study type | Retrospective chart | review | | | |
| Study sample | Patients who under December 2013. N=1094 | went laparotomy on the g | ynecologic oncology service | e at a single academic hosp | oital from January 2009 to |
| Inclusion criteria | Patients undergoing | laparotomy | | | |
| Exclusion criteria | Not reported | | | | |
| Risk tools | NSQIP | | | | |
| Outcome | Mortality Complications | | | | |
| Results | | | | | |
| | Outcome | Event rate (%) | Odds ratio (95%CI) | C-statistic | Bier score |

| Reference | Rivard 2016 ¹²⁹ | | | | | |
|-----------|----------------------------|---------------|------------------|-------|-------|--|
| | Mortality | 9 (0.8) | 1.18 (1.08-1.29) | 0.851 | 0.007 | |
| | Any complication | 368 (33.6) | 1.06 (1.04-1.08) | 0.635 | 0.323 | |
| Comments | Low overall mortalit | y event rate. | | | | |

| Reference | Saafan 2019 ¹³³ |
|--------------------|--|
| Study type | Retrospective chart review |
| Study sample | Retrospective chart review of all perforated duodenal ulcer patients at Hamad general hospital (Doha) and Alwakra hospital in Qatar using the hospitals administrative electronic database between January 2014 and December 2017. |
| Inclusion criteria | 152 patients presenting to ER and diagnosed and operated for perforated duodenal ulcers |
| Exclusion criteria | Patients < 14 years old or with perforated other organs were excluded |
| Risk tools | ASA score (≥ 3) |
| Outcome | 30 day post op morbidity |
| Results | ASA 30 day morbidity – c-statistic =0.69 (0.55–0.83), p=0.009, sensitivity = 58.82% (36.01–78.39) and Specificity = 75.56 (67.66–82.03) |
| Comments | Male patients only and includes patients over 14 years old. Low risk of bias |

| Reference | Shaker 2019 ¹⁴⁰ |
|--------------------|--|
| Study type | Retrospective review of cohort |
| Study sample | Retrospective review ACS NSQIP database from 2009 to 2013 |
| Inclusion criteria | 200 gynaecologic oncology patients 70+ years older undergoing laparotomy. |
| Exclusion criteria | None provided |
| Risk tools | ACS NSQIP surgical risk calculator |
| Outcome | 30 days any complications and mortality |
| Results | Mortality = OR 1.12 (1.01-1.25), P value= 0.03, C statistic = 0.811, Brier score = 0.015 |
| | Any complication = OR 1.06(1.02 – 1.09), P value = 0.003, C statistic = 0.652, Brier score = 0.237 |
| Comments | Female patients only of 70+ years old |

| Reference | Sharrock 2017 ¹⁴² | | | | |
|--------------------|--------------------------------|---|------------------------------------|------------------------|--|
| Study type | Retrospective cohort study | | | | |
| Study sample | Consecutive hospital N=193 | Consecutive hospital admissions were recorded between 02 January 2014 and 25 August 2015. N=193 | | | |
| Inclusion criteria | Patients were eligible | e if they were aged 70 or o | over when admitted as an emergency | for abdominal surgery. | |
| Exclusion criteria | Not reported | | | | |
| Risk tools | P-POSSUM | | | | |
| | ASA | | | | |
| Outcome | Mortality | | | | |
| Results | Mortality | | | | |
| | Outcome | Correlation | c-statistic | P value | |
| | P-POSSUM | | | | |
| | Correlation with days to death | -0.28 | | 0.21 | |
| | Mortality | | 0.784 | <0.001 | |
| | ASA | | | | |
| | Mortality | | 0.771 | <0.001 | |

| Reference | Simpson 2018 ¹⁴⁶ |
|--------------------|--|
| Study type | Retrospective review of cohort |
| Study sample | Retrospective review of the National Emergency Laparotomy Database between January 2014 to September 2016 |
| Inclusion criteria | 103 patients over 80 years old undergoing emergency laparotomy |
| Exclusion criteria | None provided |
| Risk tools | P-POSSUM |
| Outcome | Inpatient, 30 day and 90 day mortality |
| Results | Inpatient mortality = c-statistic 0.51, 30 day mortality = c-statistic 0.75, 90 day mortality c-statistic = 0.75 |
| Comments | Patients over 80 years old. |

| 2 |
|---|
| _ |

| Reference | Slim 2006 ¹⁴⁸ | | | | |
|--------------------|---|-------------------------------|---|---|--|
| Study type | Prospective cohort | study | | | |
| Study sample | Patients operated period. N=1421 | | | | |
| Inclusion criteria | Patients undergoin | ng open or laparoscopic surge | ery (electively or on emergent basis) for col | lorectal cancers or diverticular disease. | |
| Exclusion criteria | Inflammatory bowel diseases or benign polyps, because both of those conditions require specific management, and other rare colorectal diseases (volvulus, chronic constipation, etc) because they involve specific therapeutic aspects. | | | | |
| Risk tools | POSSUM P-POSSUM | | | | |
| Outcome | Mortality | | | | |
| Results | Mortality | | | | |
| | Outcome | Predicted % | Observed % (95% CI) | c-statistic | |
| | POSSUM | 11.3 | 3.4 (2.5-4.44) | n/a | |
| | P-POSSUM | 4.7 | | 0.82 | |

| Reference | Suresh 2019 ¹⁵² |
|--------------------|--|
| Study type | Retrospective chart review study |
| Study sample | All patients undergoing panniculectomy procedure at Duke University Hospital from 2005 to 2016 |
| Inclusion criteria | 264 patients who underwent panniculectomy from 2005 – 2016 were included |
| Exclusion criteria | None provided |
| Risk tools | NSQIP risk calculator |
| Outcome | 30 day post-operative any complications |
| Results | NSQIP risk calculator any complication – c-statistic =0.6193 |

| Reference | Teeuwen 2011 ¹⁵⁵ |
|--------------|---|
| Study type | Retrospective case-control study |
| Study sample | Patients older than 15 years undergoing colorectal resection between January 2003 and January 2008 in the Radboud University Nijmegen Medical Centre. |

| Reference | Teeuwen 2011 ¹⁵⁵ | | | |
|--------------------|-----------------------------|-------------|------------|--|
| | N=734 | | | |
| Inclusion criteria | Not reported | | | |
| Exclusion criteria | Not reported | | | |
| Risk tools | P-POSSUM | | | |
| Outcome | Mortality Morbidity | | | |
| Results | | | | |
| | Outcome | Predicted % | Observed % | |
| | Mortality | | | |
| | POSSUM | 17 | 0.0 | |
| | P-POSSUM | 5.9 | 8.9 | |
| | Morbidity | | | |
| | POSSUM | 46 | 39.4 | |

| Reference | Teoh 2017 ¹⁵⁶ | | | | | |
|--------------------|---|-------------------------------|--------------------|-------------|--|--|
| Study type | A retrospective chart r | A retrospective chart review | | | | |
| Study sample | All patients undergoing minimally invasive surgery on the gynecologic oncology service from January 1, 2009, to December 30, 2013. N=876 | | | | | |
| Inclusion criteria | Gynaecology oncology | patients undergoing minimally | invasive surgery | | | |
| Exclusion criteria | Not reported | Not reported | | | | |
| Risk tools | ACS NSQIP | ACS NSQIP | | | | |
| Outcome | Mortality Any complication | | | | | |
| Results | | | | | | |
| | Outcome | Event rate (%) | Odds ratio (95%CI) | C-statistic | | |
| | Mortality | 0 | n/a | n/a | | |

| Reference | Teoh 2017 ¹⁵⁶ | | | | |
|-----------|--------------------------|------------|------------------|------|--|
| | Any complication | 100 (11.4) | 1.08 (0.99-1.18) | 0.57 | |

| Reference | Tominaga 2016 ¹⁶⁰ | | | | |
|--------------------|------------------------------|---|--|--|--|
| Study type | Retrospective cohort | | | | |
| Study sample | | Between January 2009 and August 2013, patients diagnosed with colorectal cancer and underwent curative colorectal resection at the Department of Surgical Oncology of Nagasaki University Graduate School of Biological Sciences. N=239 | | | |
| Inclusion criteria | Patients over 70 years of | age diagnosed with colorectal | cancer and underwent curative colorectal resection | | |
| Exclusion criteria | Not reported | Not reported | | | |
| Risk tools | E-PASS | | | | |
| Outcome | Mortality (Survival) | | | | |
| Results | | | | | |
| | E-PASS score | Survival (%) | P value | | |
| | <0.2 | 82.9 | <0.001 | | |
| | ≥0.2 | 54.9 | <0.001 | | |

| Reference | Tran Ba Loc 2010 ¹⁶¹ |
|--------------------|--|
| Study type | Retrospective cohort study |
| Study sample | From 2002 to 2004, elderly patients undergoing major colorectal surgery in France were enrolled. N=1186 |
| Inclusion criteria | Patients, at least 65 years old, undergoing major colorectal surgery. |
| Exclusion criteria | Patients without POSSUM or follow-up data |
| Risk tools | POSSUM P-POSSUM Surgical risk score |
| Outcome | Mortality Morbidity |
| Results | |

| _ | |
|---|--|
| 2 | |

| Reference | Tran Ba Loc 2010 ¹⁶¹ | | | |
|-----------|---------------------------------|-----------|----------|----------------------|
| | Outcome | O/E ratio | P value* | c-statistic (95% CI) |
| | Morbidity | | | |
| | POSSUM | 1.22 | 0.001 | 0.75 (0.70, 0.80) |
| | Morality | | | |
| | P-POSSUM | 1.23 | 0.584 | 0.86 (0.81, 0.92) |
| | SRS | 1.08 | 0.3 | 0.78 (0.70, 0.86) |

| Reference | Vather 2006 ¹⁶⁷ | | | |
|--------------------|---|-------------------------------|-------|--|
| Study type | Retrospective cohort study | Retrospective cohort study | | |
| Study sample | Consecutive patients undergoing a major colorectal operation between January 2002 and October 2005 at the participating hospital. N=308 | | | |
| Inclusion criteria | Patients undergoing a major co | lorectal operation | | |
| Exclusion criteria | Patients with incomplete data | Patients with incomplete data | | |
| Risk tools | POSSUM P-POSSUM | | | |
| Outcome | Mortality | | | |
| Results | | | | |
| | Outcome | c-statistic | SE | |
| | POSSUM | 0.789 | 0.068 | |
| | P-POSSUM | 0.786 | 0.068 | |

| Reference | Wang 2014 ¹⁶⁹ |
|--------------------|---|
| Study type | Retrospective cohort |
| Study sample | Consecutive patients treated surgically in the study centre following a diagnosis of hilar cholangiocarcinoma. N=100 |
| Inclusion criteria | Only patients with histologically confirmed cholangiocarcinoma were included. |
| Exclusion criteria | Patients who underwent liver transplantation were not included in this study |

| Reference | Wang 2014 ¹⁶⁹ | | | |
|------------|------------------------------|--------------|----------|---------------------|
| Risk tools | POSSUM P-POSSUM E-PASS | | | |
| Outcome | Mortality Morbidity | | | |
| Results | | | | |
| | Outcome | O/E ratio | P value* | c-statistic |
| | Morbidity | | | |
| | POSSUM | 1.00 (52/52) | 0.488 | 0.843 (0.768-0.919) |
| | Morality | | | |
| | POSSUM | 1.11 (10/9) | 0.520 | 0.863 (0.766-0.961) |
| | P-POSSUM | 1.00 (10/10) | 0.721 | 0.848 (0.740-0.956) |
| | E-PASS | 1.00 (10/10) | 0.671 | 0.842 (0.735-0.949) |
| | * Goodness of fit | | | |

| Reference | Wang 2017 ¹⁷² | | |
|--------------------|---|---|--|
| Study type | Retrospective cohort | | |
| Study sample | Geriatric patients who underwent lumbar so N=242 | urgery between January 2014 and Decemb | er 2016 |
| Inclusion criteria | Elderly patients (age>60 years) with isolate | ed spinal stenosis who underwent convention | onal laminectomy without fusion. |
| Exclusion criteria | Age <60 y Lumbar spondylolisthesis Not tredecompressive laminecomy with fusion. | eated with conservative therapy for 3 mo G | lasgow Coma scale score <3. Conventional |
| Risk tools | ACS-NSQIP | | |
| Outcome | Mortality Any complication | | |
| Results | c-statistic: | | |
| | Outcome | Event rate (%) | C-statistic (95% CI) |
| | Mortality | 2 (0.8) | 0.972 (0.929, 1.000) |

| Reference | Wang 2017 ¹⁷² | | |
|-----------|--------------------------|------------|---------------------|
| | Any complication | 106 (43.8) | 0.683 (0.615,0.751) |

| Reference | Wani 2005 ¹⁷³ | | |
|--------------------|--|--|-------------------------------|
| Study type | Retrospective cohort study | | |
| Study sample | Patients of diagnosed calcular disease of b N=500 | iliary tract over an 18 month period. | |
| Inclusion criteria | The types of surgeries performed were cated TYPE-I: Cholecystectomy/ Cholecystostomy TYPE.II: Cholecystectomy with CBD explor TYPE-III: Cholecystectomy with papillotomy | y only. | ny or choledocho jujenostomy. |
| Exclusion criteria | All the operations performed were open pro | ocedures and no laparoscopic operation is in | ncluded. |
| Risk tools | POSSUM scoring system | | |
| Outcome | Morbidity Mortality | | |
| Results | Predictive accuracy | | |
| | Outcome | Sensitivity | Specificity |
| | Mortality | 62% | 94% |
| | Morbidity | 60% | 99% |
| | Correlation | | |
| | Predicted rate | Observed rate | |
| | _ (%) | Mortality (%) | Morbidity (%) |
| | 80 | 96 | 99 |
| | 70 | 84 | 87 |
| | 60 | 72 | 74 |
| | 50 | 60 | 62 |
| | 40 | 48 | 50 |
| | 30 | 36 | 37 |

| Reference | Wani 2005 ¹⁷³ | | |
|-----------|--|--------------------------------|----|
| | 20 | 24 | 25 |
| | _10 | 12 | 12 |
| | Correlation between predicted and observed | d rates is significant, p<0.05 | |

| Reference | Wolters 2006 ¹⁷⁶ | |
|--------------------|------------------------------------|---|
| Study type | Prospective cohort study | |
| Study sample | From May 1996 to June 200 N=107 | 00, patients meeting the inclusion criteria were included for analysis. |
| Inclusion criteria | patients received an aorto-b | bi-iliac or an aroto-bifemoral graft due to arterial occlusive disease |
| Exclusion criteria | Not reported. | |
| Risk tools | POSSUM ASA | |
| Outcome | Mortality | |
| | Morbidity | |
| Results | | |
| | Outcome | c-statistic |
| | Morbidity | |
| | POSSUM | 0.561 |
| | ASA | 0.518 |
| | Morality | |
| | POSSUM | 0.471 |
| | ASA | 0.590 |

| Reference | Yap 2018 ¹⁷⁷ |
|--------------|---|
| Study type | Single-centre prospective validation cohort study. |
| Study sample | Patients admitted to St Luke's Medical Center-Quezon City from January 2016 to March 2017. N=424 |

| Reference | Yap 2018 ¹⁷⁷ | | | | | | | | | |
|--------------------|---|---------------------------------|---|--|--|--|--|--|--|--|
| Inclusion criteria | Patients aged 19 years and older admitted for preoperative evaluation and cardiopulmonary risk stratification before non-cardiac surgery. | | | | | | | | | |
| | | ck surgeries, orthopaedic surge | eous abdominal surgeries, anorectal surgeries, breast ries, urologic surgeries, excision and incision biopsies of urgical procedures. | | | | | | | |
| Exclusion criteria | Ophthalmologic and endoscopic procedur | es were excluded. | | | | | | | | |
| Risk tools | ACS NSQIP risk calculator | | | | | | | | | |
| Outcome | Mortality Morbidity | | | | | | | | | |
| Results | | | | | | | | | | |
| | Outcome | Total events | c-statistic | | | | | | | |
| | Mortality | 12 (3%) | 0.89 | | | | | | | |
| | Morbidity | 60 (14%) | 0.88 | | | | | | | |

| Reference | Zattoni 2019 ¹⁷⁹ |
|--------------------|--|
| Study type | Prospective observational study |
| Study sample | All patients 70 years or older consecutively admitted to the emergency unit with an urgent need for abdominal surgery between December 2-15 and May 2016 |
| Inclusion criteria | 110 patients over 70 years old undergoing emergency abdominal surgery under general anaesthesia were enrolled |
| Exclusion criteria | Patients who underwent only medical management or who were operated on for vascular, thoracic, gynaecological or urological conditions were excluded |
| Risk tools | Age adjusted CCI ASA score |
| Outcome | 30 day mortality |
| Results | Age adjusted CCI \geq 6 30 day mortality– sensitivity = 95.2% (76.2-99.9), specificity = 48.3% (37.6-59.2) c-statistic = 71.8 ASA \geq 4 30 day mortality - sensitivity = 57.1% (34-78.2), specificity = 82% (72.5-89.4) c-statistic = 69.6 Age adjusted CCI \geq 6 90 day mortality - sensitivity = 96% (79.6-99.9), specificity = 50.6% (39.5-61.6) c-statistic = 73.3 ASA \geq 4 90 day mortality - sensitivity = 52% (31.3-72.2), specificity = 82.4% (72.6-89.8) c-statistic = 67.2 |

| A | ope | nd | ix E | | PR | OB. | AS' | Tc | hec | :kli | st | | | | | | | | | |
|--|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|----------------|
| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
| Baker 2018 ¹¹ | Υ | Υ | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Y | n/a | Y | Y | Y | Serious |
| Bennett- Guerrero 2003 ¹⁴ | Υ | Υ | Υ | Υ | Y | Y | Y | Υ | Υ | Υ | Υ | Υ | U | Υ | n/a | n/a | Υ | Υ | Υ | Low |
| Blair 2018 ¹⁷ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Y | Serious |
| Bodea 2018 ¹⁸ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | U | Υ | n/a | n/a | Υ | Y | Υ | Serious |
| Bonventur a 2019 ²⁰ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Y | U | Υ | n/a | n/a | Υ | Y | Υ | Serious |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|-------------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|-----------------|
| Boyd 2019 ²² | Υ | Υ | Y | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | U | U | U | n/a | n/a | Υ | Υ | Serious |
| Bronheim 2018 ²⁴ | Y | Υ | Υ | Y | U | U | Υ | Y | Y | Υ | Y | Υ | Y | Υ | Υ | n/a | Υ | Y | Υ | Serious |
| Bulow 2019 ²⁶ | Υ | Υ | Y | Υ | U | U | Y | Υ | Υ | Y | Υ | Υ | Υ | Y | Y | n/a | n/a | Υ | Υ | Serious |
| Cengiz 2014 ³¹ | Υ | Υ | Y | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Y | n/a | n/a | n/a | Υ | Υ | Serious |
| Chun 2018 ³² | Υ | Y | Y | Υ | U | Y | Υ | Υ | Υ | Υ | Υ | Υ | Υ | N | N | n/a | Υ | Υ | N | Very serious |
| Cologne 2015 ³⁶ | Υ | Υ | Y | Y | Y | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Y | n/a | n/a | Υ | Υ | Serious |
| Dahlke 2014 ³⁸ | Υ | Υ | Y | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Y | n/a | n/a | Υ | Υ | Low |
| Dutta 2011 ⁴³ | Υ | Υ | Y | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Y | n/a | n/a | Υ | Υ | Low |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|-------------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|----------------|
| Egberts 2011 ⁴⁵ | Υ | Υ | Y | Y | U | Y | Υ | Υ | Y | Y | Y | Υ | U | Y | Υ | n/a | n/a | Υ | Υ | Serious |
| Egberts 2011 ⁴⁶ | Υ | Υ | Υ | Y | U | Y | Υ | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Low |
| Filip 2014 ⁴⁹ | Υ | Υ | Υ | Y | U | Y | Υ | Υ | Y | Υ | Y | Υ | Υ | Y | Υ | n/a | n/a | Υ | Y | Low |
| Fu 2019 ⁵² | Υ | Υ | Υ | Y | U | Y | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Golan 2018 ⁵⁴ | Υ | Υ | Υ | Y | U | Y | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Low |
| Hirose 2014 ⁵⁷ | Υ | Υ | Y | Y | U | Y | Υ | Υ | Y | Υ | Y | Υ | U | Υ | Υ | n/a | n/a | Υ | Y | Serious |
| Hirose 2015 ⁵⁸ | Υ | Υ | Y | Y | U | Y | Υ | Υ | Y | Y | Y | N | U | Y | Υ | n/a | n/a | Υ | Y | Very serious |
| Hobson 2007 ⁶⁰ | Υ | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|--------------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|-----------------|
| Huisman 2014 ⁶⁴ | Υ | U | Υ | Y | Υ | Y | Y | Υ | Y | Υ | Υ | N | Υ | Y | Υ | n/a | n/a | Υ | Υ | Serious |
| Igari 2013 ⁶⁵ | Υ | U | Y | Y | U | Y | Υ | Y | Y | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Y | Very serious |
| Katlic 2019 ⁷² | Υ | U | Y | Y | U | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Very serious |
| Kim 2018 ⁷⁸ | Υ | Υ | Y | Y | U | Υ | Υ | Y | Υ | Υ | Υ | N | U | Υ | U | n/a | n/a | Υ | Υ | Very serious |
| Kong 2013 ⁸² | Υ | Υ | Y | Υ | U | Υ | Υ | Y | Υ | Υ | Υ | N | U | Υ | Υ | n/a | n/a | Υ | Υ | Very serious |
| Kong 2015 ⁸³ | Υ | Y | Y | Y | U | Υ | Υ | Y | Υ | Υ | Υ | N | U | N | U | n/a | n/a | Υ | Υ | Very serious |
| Kwok 2011 ⁸⁷ | Υ | U | Y | Y | U | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | Υ | U | n/a | n/a | Υ | Υ | Serious |
| Lakomkin 2018 ⁸⁸ | Υ | Υ | Y | Y | U | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|---------------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|----------------|
| Lima 2019 ⁹⁵ | Υ | U | Υ | Υ | Y | Υ | Υ | Y | Υ | Υ | Υ | N | Υ | Υ | Y | n/a | n/a | Υ | Υ | Serious |
| Markovic 2018 ⁹⁹ | Υ | Υ | N | Υ | Y | Υ | Υ | Υ | Υ | Υ | Υ | Υ | U | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Ngulube 2019 ¹¹⁰ | Υ | Υ | N | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Reis 2019 ¹²⁸ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | N | U | Υ | Υ | n/a | n/s | Υ | Υ | Very serious |
| Rivard 2016 ¹²⁹ | Υ | Y | Y | Y | U | Y | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Saafan 2019 ¹³³ | Y | U | Y | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Y | n/a | n/a | Υ | Υ | Very serious |
| Shaker 2019 ¹⁴⁰ | Υ | U | Y | Y | U | Y | Υ | Υ | Υ | Υ | Υ | N | Υ | N | Υ | n/a | U | Υ | Υ | Very serious |
| Sharrock 2017 ¹⁴² | Υ | U | Y | Y | U | Υ | Υ | Y | Υ | Υ | Υ | Υ | U | U | U | n/a | n/a | Υ | Υ | Very serious |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|---------------------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|-----------------|
| Simpson 2018 ¹⁴⁶ | Υ | U | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Slim 2006 ¹⁴⁸ | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | Y | Y | Υ | N | U | N | Y | n/a | n/a | Υ | Y | Very serious |
| Suresh 2019 ¹⁵² | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Y | Y | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Y | Low |
| Teeuwen 2011 ¹⁵⁵ | Υ | Υ | Υ | Υ | U | Υ | Y | Υ | Y | Y | Υ | N | Υ | Y | Υ | n/a | n/a | Υ | Y | Serious |
| Teoh 2017 ¹⁵⁶ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Y | Y | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Y | Serious |
| Tominaga 2016 ¹⁶⁰ | Υ | U | N | Υ | U | Υ | Y | Υ | Y | Y | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Y | Very serious |
| Tran Ba Loc 2010 ¹⁶¹ | Y | Y | Y | Y | Y | Υ | Υ | Y | Υ | Υ | Y | N | Y | N | Y | n/a | n/a | Y | Υ | Very serious |
| Vather 2006 ¹⁶⁷ | Υ | Υ | Υ | Υ | U | Υ | Υ | Υ | Υ | Υ | Υ | N | U | Υ | Υ | n/a | n/a | Υ | Υ | Serious |

| | \bigcirc |
|------------------|--------------|
| | - |
| | VICE. |
| | 8 |
| | |
| | 20 |
| | 019. |
| | 9 |
| | \cong |
| | ⊐. |
| | ight |
| | Str |
| | 57 |
| | Se |
| | Õ |
| | \geq |
| | erved. |
| | |
| | S |
| | |
| | <u>j</u> . |
| | Š |
| | Subject to N |
| ∞ | 0 |
| $\tilde{\omega}$ | 0 |
| | ₫. |
| | Се |
| | of |
| | Ť |
| | <u>.</u> |
| | ights |
| | S |
| | - |
| | |

| Study | Appropriate data sources? | Appropriate inc and exc? | Similar health across participants? | Predictors defined/ass'd same for all? | Predictor assessments made without knowledge of outcome data? | Predictors all available at time model meant to be used? | All relevant predictors analysed? | Pre-specified outcome used? | Predictors excluded from outcome definition? | Outcome defined in same way for all? | Outcome determined without knowledge of predictor information? | Reasonable number of outcome events? | Time interval between baseline and outcome appropriate? | All enrolled included in analysis? | Missing data handled appropriately? | Non-binary predictors handled appropriately? | Complexities in data accounted for? | Relevant performance measures? | Model recalibrated or likely that calibration not needed? | Overall rating |
|-----------------------------|---------------------------|--------------------------|-------------------------------------|--|---|--|-----------------------------------|-----------------------------|--|--------------------------------------|--|--------------------------------------|---|------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|---|-----------------|
| Wang 2014 ¹⁶⁹ | Y | U | Υ | Y | U | Υ | Υ | Υ | Υ | Υ | Υ | Υ | U | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Wang 2017 ¹⁷² | Υ | U | Υ | Y | U | Υ | Υ | Υ | Υ | Υ | Υ | N | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Wani 2005 ¹⁷³ | Υ | U | Υ | Y | Υ | Y | Υ | Υ | Υ | Υ | Υ | N | Υ | U | U | n/a | n/a | Υ | Υ | Very serious |
| Wolters 2006 ¹⁷⁶ | Υ | Y | Y | Y | Υ | Y | Y | Υ | Υ | Υ | Υ | N | U | Υ | Y | n/a | n/a | Υ | Υ | Serious |
| Yap 2018 ¹⁷⁷ | Υ | Υ | Υ | Y | Υ | Υ | Υ | Υ | Υ | Υ | Υ | N | U | Υ | Υ | n/a | n/a | Υ | Υ | Serious |
| Zattoni | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | Υ | n/a | n/a | Υ | Υ | Low |

Appendix F: C-statistic plots

Figure 2: POSSUM




Figure 3: P-POSSUM




Figure 4: ACS NSQIP risk calculator





Figure 5: E-PASS



2

Figure 6: ASA






Figure 7: SORT










Figure 9: Charlson comorbidity index



2

Appendix G: Calibration plots

Figure 10: POSSUM




4

5


3

Figure 11: P-POSSUM



6 7

Figure 12: ACS NSQIP risk calculator



2 Figure 13: E-PASS

1

3 4

5






Figure 14: ASA



2

Appendix H: Health economic evidence selection

Figure 15: Flow chart of health economic study selection for the guideline



^{*} Non-relevant population, intervention, comparison, design or setting; non-English language

None.

Appendix J: Excluded studies

J.1 Excluded clinical studies

1

3 Table 8: Studies excluded from the clinical review

| Reference | Reason for exclusion |
|-------------------------------------|--|
| Ahle 2019 ¹ | |
| | Inappropriate intervention |
| Al-Homoud 2004 ² | Inappropriate outcome data |
| Ali 2016 ³ | Inappropriate outcome data |
| Amrock 201 ⁴⁴ | Inappropriate study design (internal validation) |
| Anderson 2012 ⁵ | Inappropriate intervention |
| Anonymous 2018 ⁶ | No usable data |
| Anonymous 2018 ⁷ | Inappropriate intervention |
| Arakkal 2018 ⁸ | Abstract only |
| Armstrong 2019 ⁹ | Inappropriate outcome data |
| Arshad 2014 ¹⁰ | Abstract only |
| Bartlett 2014 ¹² | Inappropriate intervention |
| Bekelis 2014 ¹³ | Inappropriate intervention |
| Bihorac 2019 ¹⁵ | Inappropriate intervention |
| Blair 2016 ¹⁶ | Citation only |
| Bollschweiler 2005 ¹⁹ | Inappropriate outcome data |
| Borja-Cacho 2010 ²¹ | Inappropriate intervention |
| Brennan 2019 ²³ | Inappropriate intervention |
| Bryce 2012 ²⁵ | Inappropriate intervention |
| Burg 2019 ²⁷ | Inappropriate outcome data |
| Burgess 2017 ²⁸ | Inappropriate outcome data |
| Butterfield 2015 ²⁹ | Inappropriate intervention |
| Cao 2018 ³⁰ | Inappropriate outcome data |
| Chung 2017 ³³ | Inappropriate intervention |
| Cohen 2009 ³⁴ | Inappropriate intervention |
| Collard 2018 ³⁵ | Inappropriate outcome data |
| Cote 2019 ³⁷ | Inappropriate review population |
| de Castro 2009 ³⁹ | Inappropriate outcome data |
| Debinska 2011 ⁴⁰ | Inappropriate outcome data |
| DeLuzio 2016 ⁴¹ | Inappropriate outcome data |
| Dunn 2019 ⁴² | Inappropriate outcome data |
| Easterlin 2013 ⁴⁴ | Inappropriate intervention |
| Engin 2018 ⁴⁷ | Inappropriate outcome data |
| Farhat 2012 ⁴⁸ | Inappropriate outcome data |
| Ford 2015 ⁵⁰ | Abstract only |
| Fryer 2018 ⁵¹ | Citation only |
| Gentry 2018 ⁵³ | Systematic review: references screened |
| Hacohen Solovitz 2018 ⁵⁵ | Inappropriate outcome data |
| Harris 2019 ⁵⁶ | Inappropriate intervention |
| Hirpara 2019 ⁵⁹ | Inappropriate outcome data |

| D (| |
|-----------------------------------|--|
| Reference | Reason for exclusion |
| Hoeks 2009 ⁶¹ | Inappropriate intervention |
| Hoftman 2013 ⁶² | Inappropriate outcome data |
| Huang 2017 ⁶³ | Inappropriate outcome data |
| Inoue 2019 ⁶⁶ | Inappropriate intervention |
| Jean 2016 ⁶⁷ | Inappropriate outcome data |
| Jensen 2019 ⁶⁸ | Inappropriate intervention |
| Kalender 2014 ⁶⁹ | Inappropriate intervention |
| Kapma 2017 ⁷⁰ | Inappropriate intervention |
| Karabulut 2003 ⁷¹ | Inappropriate intervention |
| Kavanagh 2016 ⁷³ | Citation only |
| Kelly 2011 ⁷⁴ | Inappropriate intervention |
| Kertai 2003 ⁷⁵ | Inappropriate intervention |
| Khalfallah 2016 ⁷⁶ | Inappropriate intervention |
| Khene 2018 ⁷⁷ | Inappropriate outcome data |
| Klausing 2019 ⁷⁹ | Inappropriate outcome data |
| Klinceva 2006 ⁸⁰ | Inappropriate intervention |
| Knight 2009 ⁸¹ | Citation only |
| Kong 2015 ⁸³ | Inappropriate Intervention |
| Kongkaewpaisan 2019 ⁸⁴ | Inappropriate outcome data |
| Kongwibulwut 2019 ⁸⁵ | Inappropriate outcome data |
| Kurki 2002 ⁸⁶ | Inappropriate intervention |
| Lam 2004 ⁸⁹ | Inappropriate outcome data |
| Laurent 2013 ⁹⁰ | Inappropriate intervention |
| Lazarides 1997 ⁹¹ | Inappropriate outcome data |
| Le Manach 2016 ⁹² | Inappropriate intervention |
| Lee 1999 ⁹⁴ | Inappropriate intervention |
| Lee 2019 ⁹³ | Systematic review: references screened |
| Lindroth 2019 ⁹⁶ | Inappropriate intervention |
| Malik 2019 ⁹⁷ | Inappropriate outcome data |
| Marconi 2018 ⁹⁸ | Inappropriate intervention |
| Marufu 2015 ¹⁰⁰ | Inappropriate outcome data |
| Mayhew 2019 ¹⁰¹ | Systematic review: references screened |
| Meguid 2016 ¹⁰² | Inappropriate intervention |
| Meguid 2016 ¹⁰³ | Inappropriate intervention |
| Nag 2015 ¹⁰⁴ | Inappropriate study design |
| Nagashima 2005 ¹⁰⁵ | Inappropriate outcome data |
| Nashef 1999 ¹⁰⁷ | Inappropriate intervention |
| Nashef 2002 ¹⁰⁶ | Inappropriate intervention |
| Nesi 2004 ¹⁰⁹ | Inappropriate intervention |
| O'Brien 2009 ¹¹¹ | Inappropriate intervention |
| Parmar 2010 ¹¹² | Inappropriate outcome data |
| Patila 2006 ¹¹³ | Inappropriate intervention |
| Patterson 2008 ¹¹⁴ | Systematic review: references screened |
| Paul 2007 ¹¹⁵ | Inappropriate intervention |
| Pavone 2018 ¹¹⁶ | Inappropriate outcome data |
| ravulle 2010 | mappropriate outcome data |

| Reference | Reason for exclusion |
|-----------------------------------|--|
| Perkins 2004 ¹¹⁸ | Inappropriate intervention |
| Perkins 2006 ¹¹⁷ | Inappropriate intervention |
| Pillai 2015 ¹¹⁹ | Inappropriate intervention |
| Pinna-Pintor 2002 ¹²⁰ | Inappropriate intervention |
| Pliam 1997 ¹²¹ | Inappropriate intervention |
| Prabakaran 2019 ¹²² | Inappropriate intervention |
| Ranucci 2010 ¹²³ | Inappropriate intervention |
| Ranucci 2016 ¹²⁴ | Inappropriate intervention |
| Ranucci 2018 ¹²⁵ | Inappropriate intervention |
| Rasmussen 2018 ¹²⁶ | Inappropriate outcome data |
| Raymond 2019 ¹²⁷ | Inappropriate outcome data |
| Rix 2007 ¹³⁰ | Systematic review: references screened |
| Roxas 2017 ¹³¹ | Abstract only |
| Ryan 2018 ¹³² | Inappropriate outcome data |
| Sankar 2019 ¹³⁴ | Inappropriate outcome data |
| Saunders 2015 ¹³⁵ | Citation only |
| Schneider 2016 ¹³⁶ | Inappropriate outcome data |
| Sfoungaristos 2015 ¹³⁸ | Inappropriate intervention |
| Sfoungaristos 2016 ¹³⁷ | Inappropriate intervention |
| Shah 2012 ¹³⁹ | Inappropriate intervention |
| Sharma 2019 ¹⁴¹ | Inappropriate intervention |
| Shiba 2013 ¹⁴³ | Inappropriate outcome data |
| Silaschi 2015 ¹⁴⁴ | Inappropriate intervention |
| Silva Junior 2010 ¹⁴⁵ | Inappropriate review population |
| Singh 2018 ¹⁴⁷ | Inappropriate intervention |
| Sobotka 2018 ¹⁴⁹ | Inappropriate intervention |
| Srilata 2015 ¹⁵⁰ | Inappropriate intervention |
| Strilchuk 2018 ¹⁵¹ | Inappropriate outcome data |
| Suzuki 2018 ¹⁵³ | Inappropriate outcome data |
| Tambyraja 2008 ¹⁵⁴ | Systematic review: references screened |
| ter Horst 2012 ¹⁵⁷ | Inappropriate Intervention |
| Thiels 2017 ¹⁵⁸ | Inappropriate intervention |
| Tian 2014 ¹⁵⁹ | Inappropriate intervention |
| Traven 2019 ¹⁶² | |
| Tsaousi 2015 ¹⁶³ | Inappropriate intervention |
| Tyritzis 2012 ¹⁶⁴ | Inappropriate intervention |
| Vaid 2012 ¹⁶⁵ | Inappropriate intervention |
| Varela Barca 2019 ¹⁶⁶ | Inappropriate intervention |
| | Inappropriate intervention |
| Veeravagu 2017 ¹⁶⁸ | Inappropriate intervention |
| Wang 2015 ¹⁷¹ | Inappropriate intervention |
| Wang 2015 ¹⁷⁰ | Inappropriate intervention |
| Wendt 2014 ¹⁷⁴ | Inappropriate intervention |
| Wingert 2016 ¹⁷⁵ | Inappropriate outcome data |
| Ye 2019 ¹⁷⁸ | Inappropriate outcome data |
| Zhang 2014 ¹⁸⁰ | Inappropriate intervention |

| Reference | Reason for exclusion |
|---------------------------|----------------------------|
| Zheng 2013 ¹⁸¹ | Inappropriate intervention |
| Zugel 2011 ¹⁸² | Inappropriate intervention |

J.2 Excluded health economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

Table 9: Studies excluded from the health economic review

| Reference | Reason for exclusion |
|-----------|----------------------|
| None. | |

####